[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 458
1. Mithieux F, Coriat R, De La Fouchardière C, Méeus P, Rivoire M: [Pseudo-Meigs syndrome: particular management of ovarian metastases in colorectal cancer]. Gastroenterol Clin Biol; 2008 Mar;32(3):261-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudo-Meigs syndrome: particular management of ovarian metastases in colorectal cancer].
  • [Transliterated title] Le pseudosyndrome de Meigs, particularité dans la prise en charge des métastases ovariennes de cancer colorectal.
  • Ascites and/or pleural effusion with ovarian metastases in colorectal cancer are usually related to peritoneal carcinomatosis.
  • Pseudo-Meigs syndrome is a characterized by non-malignant ascites and/or pleural effusion caused by pelvic tumors other than solid benign ovarian tumors.
  • We treated two patients who developed this syndrome in a context of colorectal cancer.
  • In the presence of acellular ascites with ovarian metastases from colorectal cancer, diagnosis of pseudo-Meigs syndrome may allow surgical treatment with curative intent.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Meigs Syndrome / therapy. Ovarian Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18353585.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


2. Li W, Fan W: Using 18F-FDG positron emission tomography/computed tomography to judge benign or malignant colorectal hypermetabolic lesions. Chin J Cancer; 2010 Mar;29(3):306-11
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using 18F-FDG positron emission tomography/computed tomography to judge benign or malignant colorectal hypermetabolic lesions.
  • The thickness of the colorectal wall is unfixed because it changes following wall contractions.
  • These anatomic and physiologic factors can bring a few difficulties in correctly judging colorectal information on 18F-FDG positron emission tomography/computed tomography (PET/CT) scans.
  • This study was to discuss the imaging characteristics of colorectal hypermetabolic lesions in 18F-FDG PET/CT and their value to clinical diagnosis.
  • METHODS: According the metabolic characteristics and the shape of the lesion, 118 colorectal hypermetabolic lesions of 74 patients were detected by 18F-FDG PET/CT and separated to 6 groups (localized/CT+, localized/CT-, segmented/CT+, segmented/CT-, diffuse/CT+, diffuse/CT-).
  • CONCLUSIONS: On 18F-FDG PET/CT, colorectal hypermetabolic lesions in the diffuse/CT- or segmented/CT- groups were highly likely to be nonmalignant and those in the segmented/CT+ group were highly likely to be malignant.
  • To correctly diagnose colorectal hypermetabolic lesions, it is necessary to analyze the PET of the metabolism and the CT of the anatomy together.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Fluorodeoxyglucose F18. Multimodal Imaging / methods. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adenomatous Polyps / diagnosis. Adenomatous Polyps / radiography. Adenomatous Polyps / radionuclide imaging. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / radiography. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193115.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


3. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E, Lothe RA: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer; 2008;7:94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.
  • BACKGROUND: Multiple epigenetic and genetic changes have been reported in colorectal tumors, but few of these have clinical impact.
  • This study aims to pinpoint epigenetic markers that can discriminate between non-malignant and malignant tissue from the large bowel, i.e. markers with diagnostic potential.
  • Possible CIMP tumors were identified by comparing the methylation profile with microsatellite instability (MSI), BRAF-, KRAS-, and TP53 mutation status.
  • RESULTS: The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas.
  • The promoters of ADAMTS1, MAL, and MGMT were frequently methylated in benign samples as well as in malignant tumors, independent of microsatellite instability.
  • In contrast, normal mucosa samples taken from bowels without tumor were rarely methylated for the same genes.
  • CONCLUSION: Methylated ADAMTS1, MGMT, and MAL are suitable as markers for early tumor detection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. DNA Methylation. Early Detection of Cancer. Genes, Neoplasm. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenoma / genetics. Adult. Aged. Aged, 80 and over. Cluster Analysis. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Instability. Microsatellite Repeats / genetics. Middle Aged. Promoter Regions, Genetic. Sex Characteristics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9107-16 [17909015.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 [18003927.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S7-9 [18023574.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2429-36 [18240147.001]
  • [Cites] J Transl Med. 2008;6:13 [18346269.001]
  • [Cites] J Korean Med Sci. 2008 Apr;23(2):270-7 [18437011.001]
  • [Cites] Oncol Rep. 2008 Jun;19(6):1571-6 [18497967.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1290-301 [18486467.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Dig Liver Dis. 2001 May;33(4):372-88 [11432519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):799-803 [11440966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 [18592002.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):136-42 [18542073.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):479-85 [12904991.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 9;319(4):1327-33 [15194513.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):407-10 [15382065.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):846-53 [15386372.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):754-9 [15386381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Mol Cancer. 2004 Oct 11;3:28 [15476557.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2274-9 [16181380.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):771-8 [16207479.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2078-85 [16033773.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Genome Res. 2006 Feb;16(2):282-9 [16369045.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):593-8 [16421593.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):17-23 [16531764.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Pathol Res Pract. 2006;202(6):415-24 [16675157.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Oncol Rep. 2006 Aug;16(2):429-35 [16820927.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Aug;21(8):1334-9 [16872319.001]
  • [Cites] Gut. 2006 Oct;55(10):1467-74 [16469793.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10664-70 [17090521.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Hum Genet. 2007 Jan;120(5):701-11 [17024368.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):950-4 [17352030.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1421-7 [17487400.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5048-55 [17785556.001]
  • (PMID = 19117505.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2639620
  •  go-up   go-down


Advertisement
4. Mehrabi S, Akwe JA, Adams G Jr, Grizzle W, Yao X, Aikhionbare FO: Analysis of mtDNA sequence variants in colorectal adenomatous polyps. Diagn Pathol; 2010;5:66
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of mtDNA sequence variants in colorectal adenomatous polyps.
  • Colorectal tumors mostly arise from sporadic adenomatous polyps.
  • Adenomatous polyps are benign neoplasms that, by definition display some characteristics of dysplasia.
  • It has been shown that polyps were benign tumors which may undergo malignant transformation.
  • The ability to differentially diagnose these colorectal adenomatous polyps is important for therapeutic intervention.
  • Using high resolution restriction endonucleases and PCR-based sequencing, fifty-seven primary fresh frozen tissues of adenomatous polyps (37 tumors and 20 matched surrounding normal tissues) obtained from the southern regional Cooperative Human Tissue Network (CHTN) and Grady Memorial Hospital at Atlanta were screened with three mtDNA regional primer pairs that spanned 5.9 kbp.
  • [MeSH-major] Adenomatous Polyps / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA, Mitochondrial / analysis. Genetic Variation

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1460-5 [15489649.001]
  • [Cites] Science. 1987 Oct 9;238(4824):193-7 [2889267.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Gastroenterology. 1990 Feb;98(2):371-9 [2403953.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11164-8 [1454794.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):514-9 [9012815.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:30 [15482594.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1655-63 [15753359.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):331-7 [15956973.001]
  • [Cites] Science. 2008 May 2;320(5876):661-4 [18388260.001]
  • [Cites] Diagn Mol Pathol. 2008 Jun;17(2):94-100 [18382370.001]
  • [Cites] Carcinogenesis. 2010 Feb;31(2):296-301 [19945968.001]
  • [Cites] Hum Pathol. 2002 Mar;33(3):372-5 [11979380.001]
  • (PMID = 20929553.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / R25 GM058268
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  • [Other-IDs] NLM/ PMC2959018
  •  go-up   go-down


5. Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF: Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution. Surg Endosc; 2008 Feb;22(2):506-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution.
  • PURPOSE: Endoscopically unresectable apparently benign colorectal polyps are considered by some surgeons as ideal for their early laparoscopic colectomy experience.
  • (1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have adenocarcinoma on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
  • METHODS: Data from a consecutive series of patients undergoing laparoscopic colectomy (on an intention-to-treat basis) for endoscopically unresectable neoplasms with benign preoperative histology were retrieved from a prospective database and supplemented by chart review.
  • The median nodal harvest was 12 and all resection margins were free of neoplasm.
  • Mean diameter of benign tumors was 3.2 cm (range 0.5-10.0cm) versus 3.9cm (range 1.5-7.5cm) for adenocarcinomas (p = 0.189, t - test).
  • CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive adenocarcinoma, some of advanced stage.
  • This finding supports the practice of performing oncological resection for all patients with endoscopically unresectable neoplasms of the colorectum.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Am J Surg. 1999 May;177(5):384-7 [10365875.001]
  • [Cites] Ann Surg. 1979 Dec;190(6):679-83 [518167.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] AORN J. 1992 Dec;56(6):1068-73 [1463326.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • (PMID = 17704872.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Pillinger SH, Monson JR: Laparoscopy for colorectal malignancy. Dig Surg; 2005;22(1-2):34-40
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy for colorectal malignancy.
  • Laparoscopy for colorectal pathology is technically demanding with a steep learning curve.
  • In expert hands, there is no doubt that there is a place for laparoscopy in the operative armamentarium for the treatment of benign disease.
  • The evidence available suggests that laparoscopic resection is a feasible and appropriate option for the treatment of colorectal carcinoma.
  • [MeSH-major] Colorectal Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Anastomosis, Surgical. Clinical Competence. Humans. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838169.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 82
  •  go-up   go-down


7. Uner A, Ebinc FA, Akyurek N, Unsal D, Mentes BB, Dursun A: Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol; 2005 Sep;27(3):225-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma.
  • AIM: To analyze vascular endothelial growth factor (VEGF), c-erbB-2 and c-erbB-3 expression and to evaluate their relation to clinicopathologic parameters and pathogenesis of colorectal carcinoma.
  • METHODS: Sections of adenoma, intramucosal carcinoma and adenocarcinoma were evaluated by immunohistochemistry in 85 malignant and 37 benign colorectal neoplasms for the expression of VEGF, c-erbB-2 and c-erbB-3 considering clinicopathological variables.
  • RESULTS: VEGF was detected in comparable percentages of all neoplasm types while c-erbB-2 expression was detectable more frequently in adenoma than adenocarcinoma cases (65% vs 43%).
  • Except for the correlation of c-erbB-3 expression with Dukes' staging, there was no correlation between the studied markers and grade of differentiation, Dukes' stage and localization of colorectal adenocarcinoma. c-erbB-3 expression was seen more frequently in tubular adenomas, while c-erbB-2 expression was higher in tubulovillous and villous types.
  • CONCLUSION: These results suggest that VEGF, c-erbB-2, c-erbB-3 expression does not have prognostic value in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colorectal Neoplasms / genetics. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-3 / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Profiling. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244586.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3
  •  go-up   go-down


8. Nordenvall C, Nyrén O, Ye W: Elevated anal squamous cell carcinoma risk associated with benign inflammatory anal lesions. Gut; 2006 May;55(5):703-7
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated anal squamous cell carcinoma risk associated with benign inflammatory anal lesions.
  • BACKGROUND: The association between benign anal lesions and anal cancer is still unclear.
  • Few data from large cohort studies are available.
  • Multiple record linkages identified all incident anal (squamous cell carcinoma only) and colorectal cancers through to 2002.
  • Among inflammatory lesion and haemorrhoid patients, a significantly increased risk of colorectal cancer was observed only in the first year after hospitalisation.
  • CONCLUSIONS: Inflammatory benign anal lesions are associated with a significantly increased long term risk of anal cancer.
  • [MeSH-major] Anus Neoplasms / complications. Carcinoma, Squamous Cell / complications

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Radiol Oncol. 1984;23(5):305-13 [6095600.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] N Engl J Med. 1990 Nov 1;323(18):1228-33 [2215606.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Prog Growth Factor Res. 1992;4(2):121-37 [1338573.001]
  • [Cites] N Engl J Med. 1994 Aug 4;331(5):300-2 [8022440.001]
  • [Cites] N Engl J Med. 1995 Jan 19;332(3):190-1 [7695719.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241 [7715068.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Gut. 1997 Oct;41(4):522-5 [9391253.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1534-8 [9836490.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):1047-52 [10201481.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Br J Cancer. 2001 Aug 17;85(4):473-83 [11506482.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G626-34 [11518674.001]
  • [Cites] J Physiol Paris. 2001 Jan-Dec;95(1-6):417-22 [11595469.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G515-20 [15010360.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • (PMID = 16299038.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1856114
  •  go-up   go-down


9. D'Ambrogio A, Dorta G, Givel JC: [Colorectal stent: therapeutic alternative for acute obstruction?]. Rev Med Suisse; 2005 Jun 15;1(24):1605-7
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colorectal stent: therapeutic alternative for acute obstruction?].
  • [Transliterated title] Le stent colorectal: atternative thérapeutique en situation d'obstruction aiguë?
  • A colorectal obstruction generally requires an urgent approach, both diagnostically and therapeutically.
  • An auto-expansive stent is an effective therapeutic alternative, more often used to remove such a benign or malignant colorectal obstruction.
  • In the latter presentation, the stent allows for the removal of the obstacle and for the establishment of a precise diagnosis before surgery.
  • In the case of an incurable tumour or where removal is contra-indicated, a stent can represent a palliative treatment.
  • [MeSH-major] Colorectal Neoplasms / complications. Intestinal Obstruction / therapy. Stents

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028705.001).
  • [ISSN] 1660-9379
  • [Journal-full-title] Revue médicale suisse
  • [ISO-abbreviation] Rev Med Suisse
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 15
  •  go-up   go-down


10. Ghelase F, Mogoş DS, Mărgăritescu D, Iordache S, Ghelase MS, Râmboiu S, Mogoş G, Bică M, Săftoiu A, Georgescu I: [Correlation of adenomatous polyps and early colorectal cancer. Diagnostic and therapeutic implications]. Chirurgia (Bucur); 2009 Mar-Apr;104(2):159-65
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of adenomatous polyps and early colorectal cancer. Diagnostic and therapeutic implications].
  • [Transliterated title] Relaţia polip adenomatos--cancer colorectal precoce. Implicaţii diagnostice si terapeutice.
  • AIM: To detect the patients with colorectal adenomatous polyps or those with adenocarcinoma areas with a view to prevent and to treat the malignant disease.
  • The research method was selective screening with identification of risk factors regarding the evolution of colorectal polyps in early cancer, using colonoscopy and histopathological examination.
  • TREATMENT: Colonoscopic polypectomy was used for benign polyps and in situ carcinoma.
  • In case of adenocarcinoma is probable the invasion of submucosal lymphatics being shown a colorectal resection as appropriate.
  • CONCLUSIONS: High grade of dysplasia, the number of polyps, ulceration, bleeding, intraepithelial areas of neoplastic transformation are predictive factors for early colorectal cancer.
  • [MeSH-major] Adenomatous Polyps / diagnosis. Adenomatous Polyps / surgery. Colectomy / methods. Colonoscopy. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Carcinoma in Situ / diagnosis. Carcinoma in Situ / surgery. Cell Transformation, Neoplastic / pathology. Colonic Polyps / diagnosis. Colonic Polyps / surgery. Female. Humans. Male. Prospective Studies. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19499658.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


11. Wang W, Feng B, Li X, Yin P, Gao P, Zhao X, Lu X, Zheng M, Xu G: Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry. Mol Biosyst; 2010 Oct;6(10):1947-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry.
  • Colorectal carcinoma (CRC) is the third most commonly encountered cancer and fourth cause of cancer-associated death worldwide.
  • In this study both ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) and online affinity solid phase extraction-high performance liquid chromatography (SPE-HPLC) were used to analyze the urinary metabolites from 34 healthy volunteers, 34 benign colorectal tumor and 50 colorectal carcinoma patients to produce comprehensive metabolic profiling data.
  • [MeSH-major] Chromatography, High Pressure Liquid / methods. Colorectal Neoplasms / urine. Mass Spectrometry / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20617254.001).
  • [ISSN] 1742-2051
  • [Journal-full-title] Molecular bioSystems
  • [ISO-abbreviation] Mol Biosyst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


12. Chen HB, Liu DX, Wang L, Chen Y, Song SL, Yang LL, Hao Y, Yang JL: [Immunoreactivity of monoclonal anti-p21Ras antibody KGH-R1 in colorectal benign and malignant lesions]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Dec;26(12):1206-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunoreactivity of monoclonal anti-p21Ras antibody KGH-R1 in colorectal benign and malignant lesions].
  • AIM: To investigate the immunoreactivity of monoclonal anti-p21ras antibody KGH-R1 in colorectal benign and malignant lesions.
  • METHODS: Immunohistochemical staining was performed using monoclonal anti-p21ras antibody KGH-R1 prepared in our laboratory, in formalin-fixed, paraffin-embedded colorectal samples including normal colorectal tissues, colorectal inflammatory polyps, colorectal low-grade intraepithelial neoplasia, colorectal high-grade intraepithelial neoplasia, invasive colorectal carcinomas and corresponding adjacent tissues.
  • RESULTS: Immunostaining was found in 64.89% (61/94) of invasive colorectal adenocarcinomas with an average of 97.28% of carcinoma cells positive and average of 178.98 of HSCOREs.
  • 60.24% (50/83) of colorectal high-grade intraepithelial neoplasia demonstrated immunostaining with KGH-R1, the average percentage of positive cells was 95.08%, the average HSCOREs was 156.38.
  • 64.58% (31/48) of colorectal low-grade intraepithelial neoplasia demonstrated immunoreactivity with KGH-R1, the average percentage of positive cells was 82.52%, the average HSCOREs was 103.03.
  • 39.97% (29/73) of colorectal inflammatory polyps showed immunoreactivity with KGH-R1, the average percentage of positive cells was 17.78%, the average HSCOREs was 18.66.
  • 46.67% (21/45) of normal colorectal tissues showed immunostaining, but the immunoreactivity was very weak, the average percentage of positive cells was 2.64%, the average HSCOREs was 2.64.
  • The the average percentage of positive cells and the average HSCOREs in invasive colorectal carcinomas had no statistical significance with adjacent high-grade intraepithelial neoplasia, but were higher than that in adjacent low-grade intraepithelial neoplasia.
  • Weak immunostaining was found in 23.53% (20/85) of adjacent normal colorectal tissues.
  • CONCLUSION: Suggested in this study that monoclonal anti-p21ras antibody KGH-R1 has a high immunoreactivity with invasive colorectal carcinomas and may be a potential therapeutic antibody in the future.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Colorectal Neoplasms / immunology. Proto-Oncogene Proteins p21(ras) / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21138685.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; EC 3.6.5.2 / HRAS protein, human; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


13. Huguet KL, Metzger PP, Menke DM: Colorectal lymphangioma. Am Surg; 2007 Apr;73(4):414-6
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal lymphangioma.
  • Lymphangiomas of the colon are historically rare benign tumors.
  • [MeSH-major] Cecal Neoplasms / diagnosis. Colonoscopy. Lymphangioma / diagnosis

  • Genetic Alliance. consumer health - Lymphangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17439042.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Gundrum JD, Go R, Kwong R: Cancer in the oldest old population in the United States: Current statistics and projections. J Clin Oncol; 2009 May 20;27(15_suppl):9553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We included patients who had a previous cancer before age 85, but excluded benign tumors, myeloproliferative, and myelodysplastic neoplasms.
  • The 10 leading cancers by incidence (both sexes and decreasing order) are colorectal (388.9), lung (287.7), breast (250), prostate (211.5), urinary bladder (162.5), non-Hodgkin lymphoma (110.9), leukemia (85.1), melanoma (65), renal (46.4), and uterine (40.2).
  • The incidences of melanoma, non-Hodgkin lymphoma, renal, and lung cancers are increasing, while those of leukemia, prostate, breast, and colorectal cancers are decreasing.
  • The top 5 causes of cancer deaths are lung and bronchus (21%), colorectal (15%), pancreatic (7.1%), prostate (5.9%), and breast cancers (5.3%).
  • Cancer specific survival (CSS) has been increasing continuously since 1973 for melanoma, non-Hodgkin lymphoma, breast, colorectal, prostate, and urinary bladder cancers but decreasing in recent years for colorectal, breast, prostate, and uterine cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963637.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Skalicky T, Treska V, Liska V, Sutnar A, Molacek J, Mirka H, Ferda J, Ohlidalova K: The rare benign liver tumors. Bratisl Lek Listy; 2007;108(4-5):229-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The rare benign liver tumors.
  • As opposed to malignant secondary tumors, metastases of the colorectal carcinoma are benign tumors of the liver that are quite rare in the Czech Republic.
  • From the 55 patients operated on since 2000 at our department for benign liver tumors, the most frequent are haemangiomas, focal nodular hyperplasia (FNH) and hepatocelular adenoma.
  • Only 7.3% of them form a different histological type of a tumor than this most frequently occurring trio of tumors.
  • The authors describe three cases of rather rare liver tumors with benign behavior that have the potential of becoming malignant.
  • It concerns mucin producing biliary tumors, which correspond to the pancreatic intraductal papillary mucin tumor, hepatic cystadenoma with ovarian stroma and a liver hamartoma in an adult patient (Ref 13).
  • [MeSH-major] Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Cholangitis, Sclerosing / diagnosis. Cholangitis, Sclerosing / surgery. Cystadenoma / diagnosis. Cystadenoma / surgery. Female. Hemangioma, Cavernous / diagnosis. Hemangioma, Cavernous / surgery. Humans. Middle Aged. Pancreatic Ducts. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694811.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  •  go-up   go-down


16. Reinshagen K, Müldner A, Reinshagen S, Kähler G: Endoscopically controlled strictureplasty for stenotic colorectal anastomosis. Endoscopy; 2005 Sep;37(9):873-5
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopically controlled strictureplasty for stenotic colorectal anastomosis.
  • Various different techniques have been described for the treatment of benign colorectal anastomotic strictures.
  • A quick and effective technique is described here for the treatment of colorectal strictures.
  • [MeSH-major] Carcinoma / surgery. Colonoscopy. Intestinal Obstruction / surgery. Sigmoid Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116542.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Königsrainer I, Steurer W, Witte M, Königsrainer A: Liver resection without hilus preparation and with selective intrahepatic hilus stapling for benign tumors and liver metastasis. Langenbecks Arch Surg; 2007 Jul;392(4):485-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection without hilus preparation and with selective intrahepatic hilus stapling for benign tumors and liver metastasis.
  • Extrahepatic isolation of portal vein, hepatic artery and hepatic duct, as well as lymphadenectomy of the liver hilum are generally accepted steps of liver resection, even for metastatic and benign indications.
  • MATERIALS AND METHODS: Thirty-eight consecutive patients with resection for metastases and benign liver tumors were selected.
  • To date, no tumor recurrence was found in the hilum during the follow-up period.
  • Hilar dissection can, thus, be avoided in liver metastasis and benign liver tumors.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery. Surgical Stapling
  • [MeSH-minor] Aged. Colorectal Neoplasms / pathology. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1999 Oct;42(10):1285-90; discussion 1290-1 [10528765.001]
  • [Cites] J Surg Oncol. 2005 Apr 1;90(1):43-5 [15786414.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):137-8; author reply 138 [16371749.001]
  • [Cites] Ann Surg. 2005 Apr;241(4):582-90 [15798459.001]
  • [Cites] Br J Surg. 2006 Jun;93(6):685-9 [16703653.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):286-91 [9880776.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):202-9 [14745328.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):260-4 [16858189.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):111-9 [12832973.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):397-406; discussion 406-7 [12368667.001]
  • [Cites] World J Surg. 1995 Sep-Oct;19(5):764-7 [7571678.001]
  • [Cites] Ann Surg. 2001 Jan;233(1):45-50 [11141224.001]
  • [Cites] Ann Surg. 1996 Aug;224(2):155-61 [8757378.001]
  • [Cites] Ann Surg. 1997 Dec;226(6):704-11; discussion 711-3 [9409569.001]
  • [Cites] World J Gastroenterol. 2006 Feb 14;12(6):935-9 [16521223.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):942-5 [8813780.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):121-4 [8653335.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):210-5 [10024102.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):814-22, discussion 822-3 [16327491.001]
  • (PMID = 17530278.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Al-Kawas FH: The role of SEMS in malignant and benign colon obstruction. Acta Chir Iugosl; 2006;53(2):15-6
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of SEMS in malignant and benign colon obstruction.
  • SEMS should be avoided in benign strictures.
  • More data is needed in reference to the role of plastic expandable stents in the management of patients with benign colon strictures.
  • [MeSH-major] Colonic Diseases / therapy. Colorectal Neoplasms / complications. Intestinal Obstruction / therapy. Stents

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139878.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia and Montenegro
  • [Chemical-registry-number] 0 / Metals
  •  go-up   go-down


19. Pavlidis TE, Marakis G, Ballas K, Rafailidis S, Psarras K, Pissas D, Papanicolaou K, Sakantamis A: Safety of bowel resection for colorectal surgical emergency in the elderly. Colorectal Dis; 2006 Oct;8(8):657-62
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of bowel resection for colorectal surgical emergency in the elderly.
  • OBJECTIVE: Colorectal emergency requiring radical surgery is becoming increasingly frequent in the elderly and problems remain as regards the best management policy.
  • PATIENTS AND METHODS: In the last 23 years, 105 elderly patients, aged > or = 65 years, with colorectal disease underwent an emergency operation in our Surgical Department.
  • Forty-five patients (mean age 72 years) had benign disease and 60 patients (mean age 76.5 years) colorectal carcinoma.
  • Mostly, patients with malignant cancer presented with obstructive ileus, and patients with benign tumours with perforation and peritonitis, with a predominance of diverticulitis.
  • Forty-three percent of the patients with colorectal cancer emergency were > or = 80 years of age.
  • The mean morbidity was 25% and mortality 17%, which make up to 33% and 26.6% for benign disease, and 20% and 10% for malignant cancer, respectively.
  • CONCLUSION: Advanced age is not a contraindication to radical surgery in case of colorectal emergency in the elderly.
  • [MeSH-major] Adenocarcinoma / surgery. Colorectal Neoplasms / surgery. Colorectal Surgery / adverse effects. Emergency Treatment / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16970575.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Kume K, Murata I, Yoshikawa I, Yamasaki M, Kanda K, Otsuki M: Endoscopic piecemeal mucosal resection of large colorectal tumors. Hepatogastroenterology; 2005 Mar-Apr;52(62):429-32
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic piecemeal mucosal resection of large colorectal tumors.
  • BACKGROUND/AIMS: Since endoscopic en bloc resection of large and sessile tumors is technically difficult, endoscopic en bloc piecemeal mucosal resection (EPMR) is usually chosen for resection of such tumors.
  • Tumors resected by EPMR are, however, difficult to evaluate histologically.
  • METHODOLOGY: We removed 30 large colorectal tumors in 30 patients by EPMR between 1992-2000.
  • Patients in whom no residual tumor was found by both endoscopic and histologic examination were considered to be "cured".
  • RESULTS: Histological examination of the resected tumor tissues revealed malignancy in 43.3% (13/30).
  • Three patients had invasive malignant tumors and underwent surgery.
  • Following complete endoscopic resection, recurrences were observed in 2 patients with benign tumors, which were resected by additional endoscopic resection.
  • All patients including the two with non-invasive malignant tumors remain free from recurrence during a mean follow-up period of 45.2 months (range, 3-104 months).
  • CONCLUSIONS: EPMR of benign or non-invasive large malignant tumors is a safe and effective procedure.
  • Complete excision of large, sessile and non-invasive tumors is possible, although complete removal by EPMR cannot be verified histologically.
  • [MeSH-major] Adenoma / surgery. Carcinoma / surgery. Colorectal Neoplasms / surgery. Endoscopy, Digestive System / methods. Intestinal Mucosa / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonoscopy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816450.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


21. Consolo P, Luigiano C, Pellicano R, Ferrara F, Giacobbe G, Morace C, Pallio S, Tortora A, Melita G, Bassi M, D'Imperio N, Alibrandi A, Familiari L: Endoscopic resection as a safe and effective technique for treatment of pedunculated and non-pedunculated benign-appearing colorectal neoplasms measuring 40 mm or more in size. Minerva Med; 2010 Oct;101(5):311-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection as a safe and effective technique for treatment of pedunculated and non-pedunculated benign-appearing colorectal neoplasms measuring 40 mm or more in size.
  • AIM: The aim of this paper was to evaluate the outcome of endoscopic resection (ER) for pedunculated and non-pedunculated colorectal neoplasms exceeding 4 cm in size.
  • METHODS: All patients with a colorectal neoplasms measuring 4 cm or more, who underwent ER at our institution between January 1996 and December 2008 were included in the study.
  • The mean neoplasms size was 48.2±12.5 mm.
  • There were 32 sessile, 26 flat and 9 pedunculated neoplasms.
  • The most frequent type of neoplasm was villous adenoma (76.1%).
  • CONCLUSION: ER is a safe and effective procedure for removing benign appearing very large colorectal neoplasms.
  • [MeSH-major] Colonic Polyps / surgery. Colonoscopy. Colorectal Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Hemostasis, Surgical / methods. Humans. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Postoperative Hemorrhage / etiology. Postoperative Hemorrhage / therapy. Tumor Burden

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Minerva Med. 2011 Apr;102(2):XV. Giuseppinella, M [corrected to Melita, G]
  • (PMID = 21048553.001).
  • [ISSN] 0026-4806
  • [Journal-full-title] Minerva medica
  • [ISO-abbreviation] Minerva Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Neri E, Vagli P, Picchietti S, Vannozzi F, Linsalata S, Bardine A, Bartolozzi C: CT colonography: contrast enhancement of benign and malignant colorectal lesions versus fecal residuals. Abdom Imaging; 2005 Nov-Dec;30(6):694-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT colonography: contrast enhancement of benign and malignant colorectal lesions versus fecal residuals.
  • Mean attenuation values of benign polyps before and after contrast administration were 30 +/- 15 HU and 90 +/- 18 HU, respectively.
  • Mean attenuation values of colorectal cancer before and after contrast administration were 43 +/- 15 HU and 124 +/- 18 HU, respectively.
  • The difference in attenuation value between precontrast and postcontrast studies of polyps was statistically significant (mean 60 HU, p < 0.01); the same was true for colorectal cancer (mean 81 HU, p < 0.01).
  • The use of contrast medium could be of help in computed tomographic colonography for discriminating polypoid benign lesions and colorectal cancer from fecal residuals.
  • [MeSH-major] Colonography, Computed Tomographic / methods. Colorectal Neoplasms / radiography. Feces
  • [MeSH-minor] Colonic Polyps / radiography. Contrast Media. Diagnosis, Differential. Humans. Image Enhancement / methods. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16252141.001).
  • [ISSN] 0942-8925
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


23. Zhang W, Hart J, McLeod HL, Wang HL: Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms. Am J Clin Pathol; 2005 Jul;124(1):11-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms.
  • We immunohistochemically examined 75 human colorectal neoplasms (adenoma, 27; adenocarcinoma, 24; neuroendocrine carcinoma, 24) for the expression of activator protein (AP)-1 family proteins.
  • Nuclear and cytoplasmic expression levels of c-Jun and Fra-1 proteins were markedly elevated in adenomas, adenocarcinomas and neuroendocrine carcinomas compared with nonneoplastic colorectal epithelial cells.
  • JunB also was overexpressed in these tumors but with a predominantly cytoplasmic staining pattern.
  • Expression levels of JunD and c-Fos were high in nonneoplastic colorectal epithelial cells and remained so in neoplasms.
  • FosB was undetectable in nonneoplastic and neoplastic colorectal tissues.
  • Hierarchical clustering separated the majority of malignant from benign tumors based on AP-1 expression patterns.
  • AP-1 transcription factor family members are expressed differentially in nonneoplastic and neoplastic colorectal tissues.
  • Up-regulation of c-Jun and Fra-1 is an early event in human colorectal tumorigenesis.
  • Overexpression of Fra-2 may participate in tumor progression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Neuroendocrine / metabolism. Colorectal Neoplasms / metabolism. Epithelial Cells / metabolism. Transcription Factor AP-1 / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923159.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM63340
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-fos; 0 / Proto-Oncogene Proteins c-jun; 0 / Transcription Factor AP-1; 0 / fos-related antigen 1
  •  go-up   go-down


24. Sarli L, Pavlidis C, Cinieri FG, Regina G, Sansebastiano G, Veronesi L, Ferro M, Morari S, Violi V, Roncoroni L: Prospective comparison of laparoscopic left hemicolectomy for colon cancer with laparoscopic left hemicolectomy for benign colorectal disease. World J Surg; 2006 Mar;30(3):446-52
MedlinePlus Health Information. consumer health - Diverticulosis and Diverticulitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective comparison of laparoscopic left hemicolectomy for colon cancer with laparoscopic left hemicolectomy for benign colorectal disease.
  • BACKGROUND: Short-term outcome and anorectal function results after laparoscopic hemicolectomy for colon cancer were compared with results after laparoscopic hemicolectomy for benign diseases.
  • RESULTS: Complications were more frequent in the cancer group than in the benign disease group: overall morbidity rate (29.6% versus 8.7%; P = 0.009), diarrhea during the first 6 postoperative months (58.7% versus 34.1%; P = 0.022), and anorectal function problems (fecal incontinence and/or the inability to discriminate between gas and stool, and/or urgency, and/or tenesmus) (65.2% versus 31.7%; P = 0.002).
  • [MeSH-major] Colectomy / methods. Colonic Diseases / surgery. Colonic Neoplasms / surgery. Diverticulitis / surgery. Intestinal Polyposis / surgery. Laparoscopy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 1996 Feb;10(2):133-6 [8932614.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Dis Colon Rectum. 1996 Mar;39(3):318-22 [8603555.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):601-11 [12792435.001]
  • [Cites] Int J Surg Investig. 1999;1(3):249-50 [11341615.001]
  • [Cites] Br J Surg. 1998 Jan;85(1):92-7 [9462393.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):759-66; disscussion 767 [12454514.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1269-73 [12799886.001]
  • [Cites] Gastroenterol Clin Biol. 1986 Feb;10(2):158-76 [3516784.001]
  • [Cites] Surg Endosc. 2004 Mar;18(3):427-32 [14752626.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):697-708 [10919014.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):972-8 [12640542.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S35-46 [8831545.001]
  • [Cites] Surg Today. 1998;28(6):626-32 [9681612.001]
  • [Cites] Int J Colorectal Dis. 1988 Jun;3(2):90-5 [3411187.001]
  • [Cites] Arch Histol Cytol. 1994 Oct;57(4):405-13 [7880593.001]
  • [Cites] Dis Colon Rectum. 2003 Feb;46(2):147-55 [12576886.001]
  • [Cites] Br J Surg. 2001 Jun;88(6):801-7 [11412248.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):385-8 [12626916.001]
  • [Cites] Dis Colon Rectum. 1992 May;35(5):482-7 [1568401.001]
  • (PMID = 16479334.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Shi H, Li Y, Wei L, Sun L: Primary colorectal inflammatory myofibroblastic tumour: a clinicopathological and immunohistochemical study of seven cases. Pathology; 2010 Apr;42(3):235-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary colorectal inflammatory myofibroblastic tumour: a clinicopathological and immunohistochemical study of seven cases.
  • AIMS: Primary colorectal inflammatory myofibroblastic tumours are rare.
  • METHODS: Clinical and pathological data of seven cases of colorectal inflammatory myofibroblastic tumour were reviewed.
  • The tumour size ranged from 3.8 cm to 6.3 cm in greatest dimension.
  • Five patients were alive without evidence of disease after tumour resection.
  • Two patients had a tumour recurrence 14 and 18 months after the initial surgery, respectively.
  • CONCLUSIONS: Colorectal inflammatory myofibroblastic tumours are rare, benign or low malignant tumours and ALK positivity is helpful in pathological diagnosis.
  • [MeSH-major] Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Neoplasms, Muscle Tissue / metabolism. Neoplasms, Muscle Tissue / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350216.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


26. Øgreid D, Hamre E: Stool DNA analysis detects premorphological colorectal neoplasia: a case report. Eur J Gastroenterol Hepatol; 2007 Aug;19(8):725-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stool DNA analysis detects premorphological colorectal neoplasia: a case report.
  • Colorectal cancers usually develop from benign adenomas in a lengthy period of 5-10 years.
  • Our patient did not present any signs or symptoms of colorectal disease during his two visits to the endoscopist.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. DNA, Neoplasm / analysis. Feces / chemistry. Precancerous Conditions / diagnosis
  • [MeSH-minor] Colonic Polyps / diagnosis. Genetic Markers. Humans. Male. Middle Aged. Mutation. Neoplastic Syndromes, Hereditary / diagnosis. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625445.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


27. Hemingway DM, Jameson J, Kelly MJ, Leicester Colorectal Specialist Interest Group Project Steering Committee: Straight to test: introduction of a city-wide protocol driven investigation of suspected colorectal cancer. Colorectal Dis; 2006 May;8(4):289-95
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Straight to test: introduction of a city-wide protocol driven investigation of suspected colorectal cancer.
  • OBJECTIVE: To decrease waiting times for colorectal cancer diagnosis.
  • RESULTS: In 2001, before the pilot only 116/188 (62%) of our colorectal cancers who were referred either under the 2-week-wait arrangements or on a 'soon' basis were diagnosed within 31 days of referral.
  • In the pilot, all colorectal cancers were diagnosed within 31 days of referral, and 95% of all diagnoses (no abnormality or benign disease) were reached within 31 days of referral.
  • After full implementation 19/19 (100%) of our cancers coming through our protocol system were diagnosed within 31 days and 95% of patients with benign disease.
  • CONCLUSION: Follow-up audit of our system one and two years later shows that we now diagnose approximately 80% of our colorectal cancers who are referred under the 2 week wait or as 'soon' referrals within 31 days.
  • [MeSH-major] Clinical Protocols. Colorectal Neoplasms / diagnosis. Primary Health Care. Referral and Consultation / organization & administration. Urban Health Services
  • [MeSH-minor] Early Diagnosis. Great Britain. Humans. Pilot Projects. Program Evaluation. Time Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630232.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Agaimy A, Stoehr R, Vieth M, Hartmann A: Benign serrated colorectal fibroblastic polyps/intramucosal perineuriomas are true mixed epithelial-stromal polyps (hybrid hyperplastic polyp/mucosal perineurioma) with frequent BRAF mutations. Am J Surg Pathol; 2010 Nov;34(11):1663-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign serrated colorectal fibroblastic polyps/intramucosal perineuriomas are true mixed epithelial-stromal polyps (hybrid hyperplastic polyp/mucosal perineurioma) with frequent BRAF mutations.
  • Colorectal fibroblastic polyp and intramucosal perineurioma are 2 synonyms for a recently described benign mucosal lesion with a predilection for the rectosigmoid colon.
  • We analyzed the clinicopathological features of 29 fibroblastic polyps and investigated them for the first time for mutations known to be involved in serrated colorectal epithelial polyps (BRAF, KRAS, and PIK3CA).
  • [MeSH-major] Adenoma / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology. Epithelial Cells / pathology. Fibroblasts / pathology. Intestinal Mucosa / pathology. Mutation. Nerve Sheath Neoplasms / pathology. Proto-Oncogene Proteins B-raf / genetics. Stromal Cells / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. DNA Mutational Analysis. Female. Humans. Hyperplasia. Immunohistochemistry. Male. Middle Aged. Phosphatidylinositol 3-Kinases / genetics. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20962618.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


29. Salama M, Ormonde D, Quach T, Ee H, Yusoff I: Outcomes of endoscopic resection of large colorectal neoplasms: an Australian experience. J Gastroenterol Hepatol; 2010 Jan;25(1):84-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of endoscopic resection of large colorectal neoplasms: an Australian experience.
  • BACKGROUND AND AIMS: Endoscopic resection of large colorectal neoplasms is increasingly being used as an alternative to surgery.
  • The aim of the study was to report short- and long-term outcomes from endoscopic resection of large colorectal neoplasms from a single centre and use a model to predict mortality had surgery been performed.
  • METHODS: Consecutive patients referred for endoscopic resection of large (> or = 20 mm) colorectal neoplasms from January 2001 to February 2008 were included.
  • The Colorectal-POSSUM score was used to estimate mortality from open surgery.
  • RESULTS: There were 154 large neoplasms in 140 patients.
  • Mean neoplasm size was 26 mm (range 20-80 mm, 24 > or = 40 mm).
  • CONCLUSION: Endoscopic resection of large colorectal neoplasms is safe and effective even for very large benign neoplasms.
  • [MeSH-major] Colectomy. Colonoscopy. Colorectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793173.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


30. Amato A: Colorectal gastrointestinal stromal tumor. Tech Coloproctol; 2010 Nov;14 Suppl 1:S91-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal gastrointestinal stromal tumor.
  • Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm arising in the digestive tract, with an estimated prevalence of 15-20 per 1,000,000.
  • Colorectal GISTs represent about 5-10% of the cases, mainly located in the rectum that is the third common site.
  • Benign GISTs are more common, but many tumors are of uncertain malignant potential; tumor size and rate of mitosis are still the most reliable criteria for assessing the risk of an aggressive behavior.
  • Surgery is the first-line treatment for resectable non-metastatic colorectal GIST.
  • Segmental colectomy with negative margins is recommended, and local excision is oncologically adequate in highly selected rectal tumors.
  • [MeSH-major] Colorectal Neoplasms. Gastrointestinal Stromal Tumors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1178-86 [14515284.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):705-12 [11034250.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S37-8 [12528771.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):383-9 [11296107.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):89-96 [17145623.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2006-11 [12957454.001]
  • [Cites] Int J Colorectal Dis. 2007 Aug;22(8):981-2 [16583196.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Eur J Surg Oncol. 2004 Dec;30(10):1098-103 [15522557.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Dis Colon Rectum. 2006 May;49(5):609-15 [16552495.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):14-24 [17072676.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S60-5 [12528774.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):526-32 [17139461.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1316-9 [15793646.001]
  • [Cites] J Surg Oncol. 2009 Jan 1;99(1):42-7 [18942073.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):109-14 [16639561.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1091-5 [11021812.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):625-41 [12717247.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Feb;18(2):147-51 [12542597.001]
  • [Cites] Am J Surg. 2006 Jan;191(1):121-3 [16399120.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2325-31 [16710031.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):937-45 [10435564.001]
  • [Cites] Gastroenterol Clin Biol. 2007 Jun-Jul;31(6-7):585-93 [17646785.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):728-34 [9720500.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1922-9 [15622586.001]
  • [Cites] Pol J Pathol. 2003;54(1):3-24 [12817876.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3282-90 [15161681.001]
  • [Cites] Surg Today. 2007;37(6):455-9 [17522761.001]
  • [Cites] Surg Today. 2007;37(8):698-701 [17643218.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):66-74 [10618607.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):791-5 [10702394.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1134-42 [11048809.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):332-9 [12594669.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14 ):2012-20 [12957455.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):889-94 [15223958.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):278-81 [9891765.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8118-21 [11719439.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):947-57 [10895817.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):53-60 [9916918.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):660-7 [12949711.001]
  • [Cites] Scand J Surg. 2003;92(3):195-9 [14582540.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1339-52 [11023095.001]
  • [Cites] Colorectal Dis. 2008 Nov;10 (9):951-2 [18294266.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S83-7 [12528778.001]
  • (PMID = 20967481.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


31. Lewis MR, Deavers MT, Silva EG, Malpica A: Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol; 2006 Feb;30(2):177-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge.
  • Ovarian involvement by metastatic colorectal adenocarcinoma, although not an uncommon occurrence, remains a diagnostic challenge.
  • The gross and histologic features of such metastases overlap those of primary ovarian epithelial neoplasms such as endometrioid or mucinous adenocarcinoma.
  • The clinical and pathologic features of 86 cases of metastatic colorectal adenocarcinoma involving the ovary were reviewed.
  • Presenting symptoms included abdominal or pelvic pain (45 cases), rectal bleeding (13 cases), change in bowel habits (20 cases), and vaginal bleeding (5 cases).
  • Many involved ovaries featured smooth capsules without gross evidence of surface involvement by tumor.
  • In general, the tumors had typical histologic features of metastatic colorectal adenocarcinoma, including a garland pattern and dirty necrosis.
  • In 23 cases, foci with a benign or low malignant potential appearance were seen.
  • Immunohistochemical studies showed that 29 of 29 tumors (100%) were positive for CK20; focal CK7 positivity was seen in 5 of 30 cases (17%).
  • Metastatic colorectal adenocarcinoma should be considered in the differential diagnosis of an ovarian mass, even if the mass is large and unilateral or in a young patient, to secure proper treatment of these patients.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434891.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


32. Lewin MR, Dilworth HP, Abu Alfa AK, Epstein JI, Montgomery E: Mucosal benign epithelioid nerve sheath tumors. Am J Surg Pathol; 2005 Oct;29(10):1310-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal benign epithelioid nerve sheath tumors.
  • Mucosal nerve sheath tumors have been well described in the gastrointestinal tract and other mucosal sites.
  • In a series of mucosal biopsies, we have encountered a distinct subset of mucosal peripheral nerve sheath tumors characterized by small epithelioid cells and a benign clinical course.
  • Such epithelioid nerve sheath tumors have been observed as a component of a larger study of colorectal "schwannomas," but herein we describe them in detail.
  • A series of 7 of these lesions detected on mucosal biopsies (6 colonic, 1 bladder) was received by a single large institution in consultation material.
  • Mucosal epithelioid nerve sheath tumors are a rare entity characterized by prominent epithelioid round to oval cells with an infiltrative growth pattern.
  • These lesions are often discovered incidentally and have a benign clinical course.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Intestinal Mucosa / pathology. Nerve Sheath Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160473.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Reid-Lombardo KM, Mathis KL, Wood CM, Harmsen WS, Sarr MG: Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Ann Surg; 2010 Jan;251(1):64-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management.
  • OBJECTIVE: To estimate the frequency of extrapancreatic neoplasms in patients with IPMN compared with those with ductal pancreatic cancer and a general referral population.
  • SUMMARY BACKGROUND DATA: Several studies have reported an increased risk of extrapancreatic neoplasms in patients with IPMN, but these studies focused only on those patients who underwent resection and excluded those patients treated nonoperatively.
  • Two control groups consisting of Group 1-patients with a diagnosis of ductal pancreatic adenocarcinoma (1:1) and Group 2-a general referral population (3:1) were matched for gender and age at diagnosis, year of registration, and residence.
  • Logistic regression was used to assess the risk of a diagnosis of extrapancreatic neoplasms among cases versus controls.
  • The proportion of IPMN patients having any extrapancreatic neoplasm diagnosed before or coincident to the index date was 52% (95% CI, 47%-56%), compared with 36% (95% CI, 32%-41%) in Group 1 (P < 0.001), and 43% (95% CI, 41%-46%) in Group 2 (P = 0.002).
  • Benign neoplasms most frequent in the IPMN group were colonic polyps (n = 114) and Barrett's neoplasia (n = 18).
  • The most common malignant neoplasms were nonmelanoma skin (n = 35), breast (n = 24), prostate (n = 24), colorectal cancers (n = 19), and carcinoid neoplasms (n = 6).
  • CONCLUSIONS: Patients with IPMN have increased risk of harboring extrapancreatic neoplasms.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Carcinoma, Pancreatic Ductal / therapy. Carcinoma, Papillary / therapy. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858708.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 UL1 RR024150
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


34. Belizon A, Balik E, Horst PK, Shantha Kumara HM, Nasar A, Whelan RL: Platelet-derived growth factor (subtype BB) is elevated in patients with colorectal carcinoma. Dis Colon Rectum; 2009 Jun;52(6):1166-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet-derived growth factor (subtype BB) is elevated in patients with colorectal carcinoma.
  • PURPOSE: Platelet-derived growth factor-BB plays a role in the development of vascular and lymphatic vessels in tumors.
  • In this study plasma levels of platelet-derived growth factor-BB were assessed preoperatively in patients with adenomas and colorectal cancer to determine whether platelet-derived growth factor-BB is a useful marker or prognostic indicator.
  • METHODS: Patients with adenomas and colorectal cancer undergoing resection were assessed.
  • RESULTS: One hundred seventy-nine patients were studied (91 with colorectal cancer, 88 with adenomas).
  • Preoperative colorectal cancer platelet-derived growth factor-BB levels were higher (1,771.1 pg/ml; confidence intervals, 1,429-2,065) than in the benign neoplasm group (1083 pg/ml; confidence intervals, 933-1,192, P < 0.001).
  • In patients with colorectal cancer, a direct relationship was noted between platelet-derived growth factor-BB levels and disease severity.
  • CONCLUSION: Platelet-derived growth factor-BB levels were greater in patients with colorectal cancer (vs. patients with adenoma) and rose with increasing disease severity.
  • [MeSH-major] Adenoma / blood. Colorectal Neoplasms / blood. Platelet-Derived Growth Factor / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Chi-Square Distribution. Enzyme-Linked Immunosorbent Assay. Female. Humans. Logistic Models. Male. Proto-Oncogene Proteins c-sis. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581863.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / platelet-derived growth factor BB
  •  go-up   go-down


35. Radovanović-Dinić B, Nagorni A, Stamenković I, Zlatic A: [Synchronous colorectal adenomas]. Srp Arh Celok Lek; 2010 May-Jun;138(5-6):309-14
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous colorectal adenomas].
  • INTRODUCTION: Colorectal adenomas which are discovered simultaneously or 6 months after the diagnosis of primary adenoma or colorectal cancer (CRC) are called synchronous adenomas.
  • OBJECTIVE: The aim of the study is to show the characteristics of synchronous colorectal adenomas and to present the relation between the index rectal adenoma and the proximal synchronous tumours.
  • METHODS: The research included 114 synchronous colorectal adenomas diagnosed in 58 patients.
  • In 33 (56.9%) patients, who did not have the index tumour, the prevalence of proximal synchronous tumours was the highest (57.0%) (p < 0.001).
  • Beside the fact that synchronous adenomas are more often found distally, a great probability of finding proximal tumours shows that total colonoscopy is the method of choice for the discovery of colorectal tumours.
  • Complete colonoscopic mapping of all colorectal adenomas and their removal prevents the development of metachronous, overlooked benign CRC already present at the moment of initial diagnostics that could be the cause of the development of metachronous CRC.
  • [MeSH-major] Adenoma / pathology. Colorectal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20607974.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


36. Gelos M, Hinderberger D, Welsing E, Belting J, Schnurr K, Mann B: Analysis of albumin fatty acid binding capacity in patients with benign and malignant colorectal diseases using electron spin resonance (ESR) spectroscopy. Int J Colorectal Dis; 2010 Jan;25(1):119-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of albumin fatty acid binding capacity in patients with benign and malignant colorectal diseases using electron spin resonance (ESR) spectroscopy.
  • INTRODUCTION: In colorectal cancer (CRC), no biological marker is known that could serve both as a marker for detection and prognosis.
  • OBJECTIVE: The aim of this study was to examine whether the FA binding to albumin is detectably and significantly altered in CRC patients when compared with patients having benign colorectal diseases.
  • MATERIALS AND METHODS: One hundred four patients operatively or endoscopically treated for CRC, sigmoid diverticulitis, or a colorectal adenoma were examined before procedure.
  • RESULTS AND DISCUSSIONS: Patients with CRC showed significantly lower DR values (DR, -0.09 +/- 0.98 vs. 0.61 +/- 1.43) than patients with benign colorectal diseases, consistent with a change of conformation and transport function of albumin in CRC.
  • Within the CRC group, with advanced tumor stage, the difference in DR values increased.
  • Furthermore, a correlation with advanced tumor stage can be established.
  • [MeSH-major] Colorectal Neoplasms / metabolism. Electron Spin Resonance Spectroscopy / methods. Fatty Acids / metabolism. Serum Albumin / metabolism
  • [MeSH-minor] Aged. Demography. Endoscopy. Female. Humans. Male. Neoplasm Staging. Postoperative Care. Preoperative Care. Protein Binding

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2003 Oct 30;425(6961):905 [14586448.001]
  • [Cites] Transfus Apher Sci. 2002 Oct;27(2):129-35 [12350048.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1935-53 [17932341.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2746-8 [15987925.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1348-60 [17512720.001]
  • [Cites] Biol Pharm Bull. 2002 Jun;25(6):695-704 [12081132.001]
  • [Cites] Cancer Invest. 2007 Sep;25(6):378-83 [17882647.001]
  • [Cites] Nat Struct Biol. 1998 Sep;5(9):827-35 [9731778.001]
  • [Cites] Bull Exp Biol Med. 2004 Aug;138(2):177-8 [15662465.001]
  • [Cites] Biochim Biophys Acta. 1990 Dec 6;1036(3):228-36 [2175216.001]
  • [Cites] Clin Chem. 2006 Nov;52(11):2129-34 [16990414.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Dis Markers. 2003-2004;19(1):1-10 [14757941.001]
  • [Cites] Biochim Biophys Acta. 2000 Jun 1;1466(1-2):350-60 [10825455.001]
  • [Cites] J Mol Biol. 2006 Aug 11;361(2):336-51 [16844140.001]
  • [Cites] Gastroenterology. 2008 Aug;135(2):380-99 [18582467.001]
  • [Cites] Angew Chem Int Ed Engl. 2004 Sep 6;43(35):4616-21 [15317002.001]
  • (PMID = 19644694.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Serum Albumin
  •  go-up   go-down


37. Svendsen MN, Brünner N, Christensen IJ, Ytting H, Bentsen C, Lomholt AF, Nielsen HJ: Biological variations in plasma VEGF and VEGFR-1 may compromise their biomarker value in colorectal cancer. Scand J Clin Lab Invest; 2010 Nov;70(7):503-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological variations in plasma VEGF and VEGFR-1 may compromise their biomarker value in colorectal cancer.
  • INTRODUCTION: Vascular Endothelial Growth Factor (VEGF) plays a prominent role in tumor angiogenesis and plasma VEGF concentration may carry prognostic information in colorectal cancer.
  • The VEGF receptor 1 (VEGFR-1) is a regulatory receptor which is shredded into plasma of patients with colorectal cancer.
  • For both molecules, large biological variation and lack of standardization of assay procedures are major challenges.
  • In addition, we evaluated plasma VEGF and VEGFR-1 as markers of colorectal disease in a case-control study on four groups of 77 individuals undergoing bowel endoscopy.
  • Groups were categorized as 'no findings', 'non-malignant findings', 'adenoma', or 'colorectal cancer'.
  • In addition, we found large biological variations with CV up to 69.2% for VEGF and CV up to 35.9% for VEGFR-1.
  • CONCLUSION: There was no difference in plasma VEGF or VEGFR-1 between patients with no findings, benign disease, pre-malignant findings, and malignant findings after endoscopy.
  • The poor discrimination between patients may be explained by the large inter- and intra-subject variations found for both molecules in volunteers.
  • [MeSH-major] Biomarkers, Tumor / blood. Colorectal Neoplasms / blood. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor Receptor-1 / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20873967.001).
  • [ISSN] 1502-7686
  • [Journal-full-title] Scandinavian journal of clinical and laboratory investigation
  • [ISO-abbreviation] Scand. J. Clin. Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


38. Shen C, Hu L, Xia L, Li Y: Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients. Jpn J Clin Oncol; 2008 Nov;38(11):770-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients.
  • OBJECTIVE: To establish a sensitive method for the early detection of circulating tumor cells (CTCs) in peripheral blood (PB) of colorectal cancer (CRC) patients.
  • METHODS: PB samples were collected from 156 CRC patients, 40 benign colorectal disease patients, 40 healthy individuals and 45 patients with other solid tumors.
  • The expression of the three mRNAs in CRC patients was significantly higher than that in benign control and healthy volunteers, and the expression of survivin and CK20 was not significantly higher than that of patients with other solid tumors.
  • However, the expression of CEA mRNA was significantly higher than that of patients with other solid tumors.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / diagnosis. Microtubule-Associated Proteins / blood. Neoplasm Proteins / blood. Neoplastic Cells, Circulating / chemistry. RNA, Messenger / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Cell Line, Tumor. Female. Humans. Inhibitor of Apoptosis Proteins. Keratin-20 / blood. Keratin-20 / genetics. Leukocytes, Mononuclear / chemistry. Leukocytes, Mononuclear / cytology. Male. Middle Aged. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18845519.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Carcinoembryonic Antigen; 0 / Inhibitor of Apoptosis Proteins; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


39. Brent A, Talbot R, Coyne J, Nash G: Should indeterminate lung lesions reported on staging CT scans influence the management of patients with colorectal cancer? Colorectal Dis; 2007 Nov;9(9):816-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should indeterminate lung lesions reported on staging CT scans influence the management of patients with colorectal cancer?
  • OBJECTIVE: The aim of this study was to determine the significance of indeterminate lung lesions reported from staging CT scans on patients with colorectal cancer.
  • The tumour, node, metastasis (TNM) stage of these patients was recorded together with any follow-up scan reports or multidisciplinary team (MDT) discussions regarding these lesions.
  • In 19, the indeterminate lesions were unchanged and were therefore downgraded to benign lesions.
  • Indeterminate lung lesions are not a reason to delay surgery for colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Lung / pathology. Lung / radiography. Lung Neoplasms / secondary
  • [MeSH-minor] Humans. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Neoplasm Staging. Tomography, Spiral Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931171.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Kontzoglou K, Moulakakis KG, Alexiou D, Safioleas MC, Nikiteas N, Giahnaki AE, Kyroudes A, Kostakis A, Karakitsos P: The role of liquid-based cytology in the investigation of colorectal lesions: a cytohistopathological correlation and evaluation of diagnostic accuracy. Langenbecks Arch Surg; 2007 Mar;392(2):189-95
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of liquid-based cytology in the investigation of colorectal lesions: a cytohistopathological correlation and evaluation of diagnostic accuracy.
  • BACKGROUND AND AIMS: The role of cytologic techniques is not widely accepted even if it is well documented that the cytologic investigation of colorectal tract could complement the biopsy and increase the correct diagnosis of carcinomas.
  • This study aims to evaluate the role of Thin-Prep(R) liquid-based cytology in the investigation of colorectal lesions.
  • Based on the final diagnosis, 89 out of 93 total malignant cases and 53 out of 53 total benign cases were correctly diagnosed with Thin-Prep(R) technique (four false negatives).
  • Accurate diagnosis with biopsy was performed in 87 out of 93 total malignant cases and 53 out of 53 total benign cases with biopsy (six false negatives).
  • CONCLUSIONS: Liquid-based cytology appears to be an easy, highly accurate, and reliable cytologic method for the diagnostic approach of colorectal diseases and could be applied as complementary to biopsy for the improvement of the diagnosis.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Colorectal Neoplasms / pathology. Cytodiagnosis / methods. Microtomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1996 Jul-Aug;40(4):669-75 [8693884.001]
  • [Cites] Acta Cytol. 1996 Sep-Oct;40(5):895-9 [8842163.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):163-7 [8607439.001]
  • [Cites] Acta Cytol. 1990 Sep-Oct;34(5):620-6 [2220240.001]
  • [Cites] J Surg Oncol. 1999 May;71(1):46-9 [10362091.001]
  • [Cites] Cancer. 1978 Dec;42(6):2849-53 [728879.001]
  • [Cites] S Afr Med J. 1979 Apr 14;55(16):619-23 [462273.001]
  • [Cites] Acta Cytol. 1997 Jul-Aug;41(4):1167-70 [9250316.001]
  • [Cites] Mod Pathol. 1996 Mar;9(3):304-6 [8685232.001]
  • [Cites] Acta Cytol. 2000 Jan-Feb;44(1):46-50 [10667159.001]
  • [Cites] Acta Cytol. 2002 Jul-Aug;46(4):693-6 [12146033.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2504-9 [6291742.001]
  • [Cites] Mod Pathol. 1995 Apr;8(3):270-4 [7617653.001]
  • [Cites] Diagn Cytopathol. 1997 Apr;16(4):368-71 [9143834.001]
  • [Cites] Gastrointest Endosc. 1972 Nov;19(2):77-8 [4648832.001]
  • [Cites] Singapore Med J. 2000 Dec;41(12):575-8 [11296781.001]
  • [Cites] Diagn Cytopathol. 1998 Jan;18(1):24-32 [9451555.001]
  • [Cites] Dis Colon Rectum. 1997 May;40(5):609-13 [9152193.001]
  • [Cites] Diagn Cytopathol. 2001 Feb;24(2):137-41 [11169896.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1563-7 [2208009.001]
  • [Cites] Gastrointest Endosc. 1987 Oct;33(5):370-1 [3678764.001]
  • [Cites] Gut. 1991 Jul;32(7):745-8 [1855680.001]
  • (PMID = 17294213.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


41. Toll A, Real FX: Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next? Cell Cycle; 2008 Sep 1;7(17):2674-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next?
  • Somatic oncogenic activating mutations in FGFR3 and/or PIK3CA have recently been described in benign epithelial cutaneous lesions that never progress to malignancy (seborrheic keratoses and epidermal nevi).
  • The same mutations have been observed in malignant neoplasms from other tissues (bladder carcinoma, cervix cancer, colorectal cancer, myeloma).
  • However, many of the abovementioned epithelial benign cutaneous tumors do not harbour mutations in FGFR3 or PIK3CA.
  • [MeSH-major] Mutation / genetics. Skin Neoplasms / genetics. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728396.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 82
  •  go-up   go-down


42. Rosin D, Khaikin M, Zmora O: Minimally invasive approach to colorectal surgery. Minerva Chir; 2008 Apr;63(2):127-49
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive approach to colorectal surgery.
  • Laparoscopy for colorectal surgery gained much less acceptance.
  • The aim of this review was to describe some general aspects of laparoscopic colorectal surgery, and examine the data supporting its use in different procedures for various pathologies, both benign and malignant.
  • [MeSH-minor] Anastomosis, Surgical / methods. Colorectal Neoplasms / surgery. Colostomy / methods. Diverticulitis, Colonic / surgery. Evidence-Based Medicine. Humans. Inflammatory Bowel Diseases / surgery. Intestinal Volvulus / surgery. Length of Stay. Minimally Invasive Surgical Procedures / methods. Quality of Life. Rectal Prolapse / surgery. Safety. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18427445.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 104
  •  go-up   go-down


43. Meijerink MR, van Waesberghe JH, Golding RP, van der Weide L, van den Tol P, Meijer S, van Kuijk C: Subtraction-multiphase-CT unbeneficial for early detection of colorectal liver metastases. Eur J Radiol; 2010 Jun;74(3):e132-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtraction-multiphase-CT unbeneficial for early detection of colorectal liver metastases.
  • PURPOSE: To assess the value of multiphase-subtraction-CT for early detection of colorectal-liver-metastases (CRLM).
  • Two experienced radiologists initially reviewed the conventional 4-phase-CT for malignant and/or benign appearing lesions and at least 1-month hereafter the same 4-phase-CT now including the subtracted images.
  • [MeSH-major] Carcinoma / radiography. Carcinoma / secondary. Colorectal Neoplasms / radiography. Early Detection of Cancer / methods. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19515521.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


44. Wichmann MW, Hüttl TP, Winter H, Spelsberg F, Angele MK, Heiss MM, Jauch KW: Immunological effects of laparoscopic vs open colorectal surgery: a prospective clinical study. Arch Surg; 2005 Jul;140(7):692-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunological effects of laparoscopic vs open colorectal surgery: a prospective clinical study.
  • HYPOTHESIS: Laparoscopy has become a popular approach for the surgical treatment of benign and even malignant colorectal diseases.
  • Several authors have reported better preserved immunity in patients undergoing laparoscopic compared with conventional colorectal surgery.
  • The present study addresses the hypothesis that specific and nonspecific immunity are differently affected by laparoscopic and conventional colorectal surgery.
  • PATIENTS: Seventy prospectively enrolled patients with colorectal diseases undergoing laparoscopic (n = 35) or open (n = 35) surgery.
  • The levels of B lymphocytes and T lymphocytes and helper T-cell counts and cytotoxic (suppressor) T-cell counts did not show significant differences after open or laparoscopic surgery.
  • These findings are important because a divergent effect on specific and nonspecific immunity of laparoscopic surgery for colorectal disease has not been reported before.
  • [MeSH-major] Colorectal Neoplasms / immunology. Colorectal Neoplasms / surgery. Immunity, Cellular / physiology. Laparoscopy / methods. Laparotomy / methods. Postoperative Complications / immunology
  • [MeSH-minor] Aged. Analysis of Variance. Biomarkers / blood. Female. Hospitals, University. Humans. Immunocompetence / physiology. Inflammation Mediators / analysis. Male. Middle Aged. Neoplasm Staging. Probability. Prognosis. Prospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16027336.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Inflammation Mediators
  •  go-up   go-down


45. Alves A, Panis Y, Mathieu P, Mantion G, Kwiatkowski F, Slim K, Association Française de Chirurgie: Postoperative mortality and morbidity in French patients undergoing colorectal surgery: results of a prospective multicenter study. Arch Surg; 2005 Mar;140(3):278-83, discussion 284
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative mortality and morbidity in French patients undergoing colorectal surgery: results of a prospective multicenter study.
  • HYPOTHESIS: Better knowledge of independent risk factors might decrease mortality and morbidity rates following colorectal surgery.
  • INTERVENTIONS: From June to September 2002, consecutive patients undergoing open or laparoscopic surgery (electively or on an emergent basis) for colorectal cancers or diverticular disease were prospectively included.
  • Exclusion criteria were colectomy for other causes (eg, inflammatory bowel diseases, benign polyps).
  • CONCLUSION: Colorectal resection in France is associated with a 3.4% mortality rate and a 35% morbidity rate.
  • [MeSH-major] Colorectal Neoplasms / surgery. Diverticulum, Colon / surgery. Postoperative Complications / mortality


46. Galamb O, Sipos F, Solymosi N, Spisák S, Krenács T, Tóth K, Tulassay Z, Molnár B: Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2835-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results.
  • EXPERIMENTAL DESIGN: Total RNA was extracted, amplified, and biotinylated from frozen colonic biopsies of patients with colorectal cancer (n=22), adenoma (n=20), hyperplastic polyp (n=11), inflammatory bowel disease (n=21), and healthy normal controls (n=11), as well as peripheral blood samples of 19 colorectal cancer and 11 healthy patients.
  • Between low-grade and high-grade dysplastic adenomas, 65 classifier probesets such as aquaporin 1, CXCL10, and APOD (90.91/100) were identified; between colorectal cancer and adenoma, 61 classifier probesets including axin 2, von Willebrand factor, tensin 1, and gremlin 1 (90.91/100) were identified.
  • Early- and advanced-stage colorectal carcinomas could be distinguished using 34 discriminatory transcripts (100/66.67).
  • [MeSH-major] Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology. RNA, Messenger
  • [MeSH-minor] Adenoma / blood. Adenoma / genetics. Adenoma / pathology. Biomarkers, Tumor / analysis. Biopsy. Case-Control Studies. Chi-Square Distribution. Colonic Polyps / blood. Colonic Polyps / genetics. Colonic Polyps / pathology. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Inflammatory Bowel Diseases / blood. Inflammatory Bowel Diseases / pathology. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843029.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


47. Darwood RJ, Borley NR: TEMS: an alternative method for the repair of benign recto-vaginal fistulae. Colorectal Dis; 2008 Jul;10(6):619-20
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TEMS: an alternative method for the repair of benign recto-vaginal fistulae.
  • COMMENTS: TEMS is a useful technique for the repair of benign recto-vaginal fistula and has distinct advantages over conventional techniques.
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Anal Canal. Female. Humans. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294273.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Kazaryan AM, Pavlik Marangos I, Rosseland AR, Røsok BI, Mala T, Villanger O, Mathisen O, Giercksky KE, Edwin B: Laparoscopic liver resection for malignant and benign lesions: ten-year Norwegian single-center experience. Arch Surg; 2010 Jan;145(1):34-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic liver resection for malignant and benign lesions: ten-year Norwegian single-center experience.
  • BACKGROUND: The introduction of laparoscopic liver resection has been challenging because new and safe surgical techniques have had to be developed, and skepticism remains about the use of laparoscopy for malignant neoplasms.
  • We present herein a large-volume single-center experience with laparoscopic liver resection.
  • One hundred thirteen patients had malignant lesions, of whom 96 had colorectal metastases.
  • INTERVENTION: Laparoscopic liver resection for malignant and benign lesions.
  • Tumor-free resection margins determined by histopathologic evaluation were achieved in 140 of 149 malignant specimens (94.0%).
  • The 5-year actuarial survival for patients undergoing procedures for colorectal metastases was 46%.
  • Perioperative morbidity and mortality and long-term survival after laparoscopic resection of colorectal metastases appear to be comparable to those after open resections.
  • [MeSH-major] Colorectal Neoplasms / surgery. Hepatectomy / methods. Liver Diseases / surgery. Liver Neoplasms / surgery


49. Ohta M, Seto M, Ijichi H, Miyabayashi K, Kudo Y, Mohri D, Asaoka Y, Tada M, Tanaka Y, Ikenoue T, Kanai F, Kawabe T, Omata M: Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology; 2009 Jan;136(1):206-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression.
  • BACKGROUND & AIMS: Although colorectal cancer (CRC) progression has been associated with alterations in KRAS and RAS signaling, not all CRC cells have KRAS gene mutations.
  • The expression of the RAS protein activator like-1 (RASAL1) was examined in clinical colorectal neoplasms using immunohistochemistry.
  • The clinicopathologic (age, sex, and tumor site and grade) and molecular (KRAS gene mutation, as well as CTNNB1 and TP53 expression patterns) factors that could affect RASAL1 expression were examined.
  • RASAL1 expression was detected in 46.9% (30/64) of adenocarcinoma, 17.4% (8/46) of large adenoma, and no (0/42) small adenoma samples.
  • RASAL1 expression levels were correlated with the presence of wild-type KRAS gene in CRC tumor samples (P= .0010), distal location (P= .0066), and abnormal expression of TP53 (P= .0208).
  • Reductions in RASAL1 expression were detected more frequently in advanced lesions than in small adenomas, suggesting that RASAL1 functions in the progression of benign colonic neoplasms.
  • [MeSH-major] Colorectal Neoplasms / etiology. Tumor Suppressor Proteins / physiology. ras GTPase-Activating Proteins / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. DNA Methylation. Disease Progression. Female. Gene Silencing. Genes, ras. Humans. Male. Middle Aged. Signal Transduction


50. Gottwald L, Korczyński J, Góra E, Bieńkiewicz A: [Adnexal tumors after surgical treatment of colorectal cancer]. Ginekol Pol; 2008 Apr;79(4):259-63
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adnexal tumors after surgical treatment of colorectal cancer].
  • OBJECTIVE: The risk of metastatic ovarian tumor is significantly higher in case of women with a history of colorectal cancer.
  • DESIGN: The purpose of the study was to evaluate the clinical presentation and histopathology of adnexal tumors in case of female patients with a history of colorectal adenocarcinoma.
  • MATERIAL AND METHODS: A retrospective study on 13 women (each with a history of colorectal carcinoma, operated due to adnexal tumor between 2004 and 2007), has been conducted.
  • Subject characteristics, ultrasound, CT, serum tumor markers levels, histopathology and findings at surgery were analyzed.
  • RESULTS: Time distance between colorectal cancer surgery and ovarian tumor operation - measured in months -was shorter in cases of malignant neoplasms (10.13 +/- 3.98) than in benign tumors (26.2 +/- 19.37).
  • Ultrasound examination showed solid-cystic adnexal tumors in 8 malignant cases, and ovarian cysts in 5 benign conditions.
  • Unilateral adnexectomy only took place in one case of benign tumor and in one case of disseminated neoplasmatic disease.
  • CONCLUSIONS: When evaluating a patient with an adnexal tumor, a history of malignancy strongly suggests a metastatic nature.
  • The use of ultrasound associated with plasma levels of Ca 125, Ca 19-9 and CEA, represents a useful method of preoperative assessment of ovarian tumors.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Female. Humans. Middle Aged. Neoplasm Staging. Poland. Retrospective Studies. Risk Assessment. Ultrasonography, Doppler, Color / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592863.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


51. Kurimoto M, Fukuda I, Hizuka N, Takano K: The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr J; 2008 Mar;55(1):67-71
Genetic Alliance. consumer health - Acromegaly.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence of benign and malignant tumors in patients with acromegaly at a single institute.
  • It has been reported that patients with acromegaly may have an increased risk of developing several types of cancers, such as colorectal, breast and prostate tumors.
  • In this study, we determined the prevalence of benign and malignant neoplasms in patients with acromegaly.
  • Of the benign tumors, multinodular goiter and colonic, gastric and gallbladder polyps were observed in 57% (47/83), 40% (35/87), 23% (10/43), and 14% (11/77) [corrected] of the patients, respectively.
  • [MeSH-major] Acromegaly / complications. Acromegaly / epidemiology. Neoplasms / complications. Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / complications. Breast Neoplasms / epidemiology. Carcinoma / complications. Carcinoma / epidemiology. Colonic Neoplasms / complications. Colonic Neoplasms / epidemiology. Female. Humans. Incidence. Leiomyosarcoma / complications. Leiomyosarcoma / epidemiology. Male. Middle Aged. Prevalence. Retrospective Studies. Stomach Neoplasms / complications. Stomach Neoplasms / epidemiology. Thyroid Diseases / complications. Thyroid Diseases / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Endocr J. 2008 Aug;55(4):786
  • (PMID = 18202526.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


52. Bretthauer M, Hoff G: [Prevention and early diagnosis of colorectal cancer]. Tidsskr Nor Laegeforen; 2007 Oct 18;127(20):2688-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prevention and early diagnosis of colorectal cancer].
  • BACKGROUND: Colorectal cancer (CRC) is one of the most common cancers in Norway.
  • CRC develops from benign adenomas in the colon over a long time.
  • MATERIAL AND METHODS: Medline was systematically searched using the MeSH terms "Colorectal neoplasm AND prevention and control", with a limitation on randomised trials in humans.
  • [MeSH-major] Colorectal Neoplasms
  • [MeSH-minor] Colon / radiography. Colonoscopy. Early Diagnosis. Evidence-Based Medicine. Humans. Mass Screening. Occult Blood. Prognosis. Randomized Controlled Trials as Topic. Sigmoidoscopy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952153.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 35
  •  go-up   go-down


53. Zhang JF, Gao CF, Wang XL, Zheng GB, Li DH: [Screening and expression of tumor markers in colorectal carcinoma]. Zhonghua Wai Ke Za Zhi; 2007 Apr 1;45(7):459-61
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Screening and expression of tumor markers in colorectal carcinoma].
  • OBJECTIVE: To screen the tumor markers of colorectal carcinoma and to investigate their expression in preoperative and postoperative serum.
  • METHODS: The distinct proteins in serum were detected in 87 cases of colorectal carcinoma, 68 cases of benign colorectal diseases and 56 healthy people by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS).
  • The distinct proteins in serum were detected in 87 cases of colorectal carcinoma pre-operation and within 15 days post operation with the same methods.
  • Compared with benign colorectal diseases and healthy control, the expression of the two proteins was obviously up-regulated in colorectal carcinoma (P < 0.01).
  • Compared with pre-operation, the expression on the 1(st) day post operation was obviously up-regulated (P < 0.01), and the expression decreased to pre-operative level on the 4(th) day post operation.
  • CONCLUSIONS: Two proteins with mass-to-charge ratios of 5955 Da and 5972 Da could be regarded as tumor markers in colorectal carcinoma, the expression may has some regularity.
  • [MeSH-major] Biomarkers, Tumor / blood. Colorectal Neoplasms / blood. Mass Screening / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17686301.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


54. McIntosh J, Sylvester PA, Virjee J, Callaway M, Thomas MG: Pulmonary staging in colorectal cancer--is computerised tomography the answer? Ann R Coll Surg Engl; 2005 Sep;87(5):331-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary staging in colorectal cancer--is computerised tomography the answer?
  • INTRODUCTION: Pulmonary staging in colorectal cancer (CRC) has traditionally been carried out by means of plain chest radiograph (CXR), although computerised tomography (CT) imaging of the chest is increasingly being performed for this purpose.
  • Patients with a CRC went on to have a staging intravenous, contrast-enhanced CT of the chest, abdomen and pelvis prior to an out-patient appointment with a colorectal surgeon.
  • In addition, one of the patients underwent multiple, non-diagnostic thoracic investigations prior to a diagnosis of sarcoidosis being made and then proceeding to surgery.
  • An independent consultant radiologist reviewed seven out of the nine CXRs of patients with an abnormality on thoracic CT without knowledge of the clinical diagnosis, and reported three of the CXRs to be normal.
  • However, CT is likely to identify more benign radiological abnormalities than CXR alone, and investigations should not occur to the detriment of treating the primary tumour.
  • [MeSH-major] Colorectal Neoplasms. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Neoplasm Staging / standards. Prospective Studies. Sensitivity and Specificity


55. Avoranta T, Sundström J, Korkeila E, Syrjänen K, Pyrhönen S, Laine J: The expression and distribution of group IIA phospholipase A2 in human colorectal tumours. Virchows Arch; 2010 Dec;457(6):659-67
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression and distribution of group IIA phospholipase A2 in human colorectal tumours.
  • The expression profile of this protein, however, is controversial in colorectal carcinoma.
  • The aim of this study was to examine the distribution and expression of IIA PLA2 protein in benign, premalignant and malignant colorectal tumours as well as in peritumoural mucosa.
  • Seven hyperplastic polyps, 24 adenomas and 83 colorectal carcinomas were stained with immunohistochemistry (IHC) for IIA PLA2.
  • A total of 79% of adenomas and 31% of carcinomas showed IIA PLA2-immunopositive tumour cells in IHC, and the expression was localised to epithelial cells with ISH.
  • Our results suggest that the IIA PLA2 protein content is dramatically decreased in malignant colorectal tumours as compared with adenomas.
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Colorectal Neoplasms / metabolism. Group II Phospholipases A2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Inflammation. 1993 Aug;17 (4):453-64 [8406689.001]
  • [Cites] Cell. 1995 Jun 16;81(6):957-66 [7781071.001]
  • [Cites] Front Biosci. 2008 May 01;13:4144-74 [18508504.001]
  • [Cites] J Carcinog. 2009;8:5 [19332896.001]
  • [Cites] J Biochem. 1992 Sep;112(3):350-4 [1429522.001]
  • [Cites] J Immunol. 1999 Jun 15;162(12 ):7402-8 [10358193.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):212-20 [15475936.001]
  • [Cites] Carcinogenesis. 2009 Mar;30(3):377-86 [19136477.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16203-8 [12456890.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):130-6 [12591965.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12 ):3857-61 [11751475.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2636-43 [15805260.001]
  • [Cites] Ann Oncol. 2009 Jul;20(7):1230-5 [19276398.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98 (7):3935-9 [11274413.001]
  • [Cites] Cancer Res. 1990 Nov 15;50(22):7232-5 [1977517.001]
  • [Cites] Nat Genet. 1997 Sep;17 (1):88-91 [9288104.001]
  • [Cites] J Infect Dis. 2002 Jun 15;185(12 ):1767-72 [12085323.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5184-6 [7585570.001]
  • [Cites] Drug Discov Today. 2003 Aug 1;8(15):710-6 [12927514.001]
  • [Cites] Mol Carcinog. 2007 Feb;46(2):106-16 [17091473.001]
  • [Cites] Am J Gastroenterol. 1999 Mar;94(3):713-20 [10086656.001]
  • [Cites] Oncogene. 1998 Oct 15;17 (15):2009-12 [9788445.001]
  • [Cites] Clin Chem. 1992 Sep;38(9):1824-9 [1526020.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):500-3 [9458096.001]
  • [Cites] Cancer Lett. 2006 Nov 18;243(2):255-63 [16458424.001]
  • [Cites] Adv Exp Med Biol. 1990;275:17-34 [2239445.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1084-91 [10706128.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11280-5 [11005842.001]
  • [Cites] Clin Infect Dis. 1993 Nov;17 (5):864-70 [8286627.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):545-8 [11520087.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92 (2):289-92 [9040208.001]
  • [Cites] Oncogene. 2000 Jun 29;19(28):3182-92 [10918573.001]
  • [Cites] J Rheumatol. 1993 Feb;20(2):325-30 [8474071.001]
  • [Cites] APMIS. 2009 Mar;117(3):151-61 [19245588.001]
  • [Cites] Cell. 1993 Nov 19;75(4):631-9 [8242739.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2009 Jul-Aug;57(4):291-4 [19578817.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):667-71 [11839587.001]
  • [Cites] Gut. 1997 Jan;40(1):95-101 [9155583.001]
  • [Cites] Biochim Biophys Acta. 1998 May 27;1403(1):47-56 [9622592.001]
  • [Cites] Biochim Biophys Acta. 2005 Apr 15;1733(2-3):210-23 [15863368.001]
  • [Cites] Lab Invest. 1995 Feb;72 (2):201-8 [7853853.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5A):3179-85 [17970059.001]
  • [Cites] World J Gastroenterol. 2009 Dec 21;15(47):5898-906 [20014453.001]
  • [Cites] Gut. 1994 Nov;35(11):1593-8 [7828979.001]
  • [Cites] APMIS. 1998 Aug;106(8):780-4 [9744764.001]
  • (PMID = 20938784.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.1.1.4 / Group II Phospholipases A2
  •  go-up   go-down


56. La Vecchia C, Bosetti C: Oral contraceptives and neoplasms other than breast and female genital tract. Eur J Cancer Prev; 2009 Sep;18(5):407-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral contraceptives and neoplasms other than breast and female genital tract.
  • We reviewed epidemiological data on oral contraceptive (OC) use and colorectal, liver, lung and other nonfemale neoplasms.
  • The data for colorectal cancer are suggestive of a favourable effect of OC, in the absence, however, of any duration-risk relation.
  • Current, but not past, OC use is associated with excess risk of benign liver tumours, and a modest excess risk of liver cancer.
  • There was no evidence of an association between OC use and lung, digestive tract neoplasms other than colorectum, cutaneous malignant melanoma, thyroid cancer and any of the other neoplasms investigated.
  • [MeSH-major] Colorectal Neoplasms / epidemiology. Contraceptives, Oral / therapeutic use. Liver Neoplasms / epidemiology. Lung Neoplasms / epidemiology
  • [MeSH-minor] Breast Neoplasms / epidemiology. Female. Genital Neoplasms, Female / epidemiology. Humans. Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609214.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contraceptives, Oral
  • [Number-of-references] 49
  •  go-up   go-down


57. Ishikawa K, Kamohara Y, Tanaka F, Haraguchi N, Mimori K, Inoue H, Mori M: Mitotic centromere-associated kinesin is a novel marker for prognosis and lymph node metastasis in colorectal cancer. Br J Cancer; 2008 Jun 3;98(11):1824-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitotic centromere-associated kinesin is a novel marker for prognosis and lymph node metastasis in colorectal cancer.
  • Overexpression of MCAK has been correlated with aggressive forms of carcinoma, resulting in poor prognosis of colorectal cancer.
  • The purpose of this study was to quantify MCAK expression in malignant and benign colorectal tissues and to determine if MCAK expression levels correlate with clinicopathologic factors and prognosis in colorectal cancer patients.
  • Paired colorectal tissue samples from tumours and the corresponding normal tissues were obtained from 120 patients with colorectal cancer who underwent surgical resection.
  • MCAK expression was higher in colorectal cancer tissue (P<0.01) than in corresponding normal tissue, and this elevated expression level was markedly associated with factors such as lymph node metastasis (P=0.0023), venous invasion (P=0.019), peritoneal dissemination (P=0.021) and Dukes' classification (P=0.0023).
  • These data suggest that MCAK expression may serve as a good marker of prognosis and lymph node metastasis in colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / metabolism. Kinesin / genetics. RNA, Messenger / analysis
  • [MeSH-minor] Cell Line, Tumor. Humans. Immunohistochemistry. Lymphatic Metastasis. Multivariate Analysis. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2001 Jan;3(1):E28-34 [11146647.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):62-70 [17944972.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4041-7 [12124339.001]
  • [Cites] Mol Biol Cell. 2002 Aug;13(8):2718-31 [12181341.001]
  • [Cites] EMBO J. 2004 Feb 11;23(3):627-37 [14749730.001]
  • [Cites] Curr Biol. 2004 May 4;14(9):R346-8 [15120087.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Jun;31(6):840-6 [15222098.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):282-6 [15199388.001]
  • [Cites] J Cell Biol. 2004 Oct 11;167(1):19-22 [15479732.001]
  • [Cites] Gastroenterology. 1993 Sep;105(3):820-6 [8359652.001]
  • [Cites] Oncogene. 1993 Oct;8(10):2821-6 [8378090.001]
  • [Cites] J Cell Biol. 1995 Jan;128(1-2):95-104 [7822426.001]
  • [Cites] Br J Cancer. 1997;76(4):531-6 [9275032.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:745-77 [9442886.001]
  • [Cites] EMBO J. 2005 Mar 23;24(6):1256-66 [15775983.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4683-9 [15930286.001]
  • [Cites] Cell Mol Life Sci. 2005 Dec;62(24):3039-56 [16314924.001]
  • [Cites] Nature. 2006 May 4;441(7089):115-9 [16672973.001]
  • [Cites] Br J Cancer. 2007 Aug 20;97(4):543-9 [17653072.001]
  • [Cites] Am J Surg. 2007 Dec;194(6):827-31; discussion 831-2 [18005779.001]
  • [Cites] J Cell Biol. 2007 Dec 3;179(5):869-79 [18039936.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • (PMID = 18506187.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KIF2C protein, human; 0 / RNA, Messenger; EC 3.6.1.- / Kinesin
  • [Other-IDs] NLM/ PMC2410130
  •  go-up   go-down


58. John SK, Jones OM, Fay H, Howell RD, Fozard JB: Should we pursue patients who fail to attend colorectal clinics? A 9-year study. Ann R Coll Surg Engl; 2007 Jul;89(5):484-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should we pursue patients who fail to attend colorectal clinics? A 9-year study.
  • INTRODUCTION: No uniform protocol exists on how to deal with patients who fail to attend colorectal clinics.
  • Our aim was to identify whether the tendency to 'failure to attend' (FTA) in the colorectal clinic was associated with FTA in other clinics and also whether FTA patients have serious pathology.
  • PATIENTS AND METHODS: This was a retrospective study of a prospectively recorded list of FTA patients, in colorectal urgent or two-week wait clinics from 1996-2004.
  • Of these, 61 (40.4%) were colorectal referrals, 76 (50.3%) were general surgical referrals, and for 14 (9.3%) case notes were not available.
  • There were 59 FTA episodes in 61 colorectal patients associated with 59 FTA episodes in other clinics (Pearson correlation: r = 0.411; P = 0.01, two-tailed, SPSS v.12).
  • Of 58 colorectal outcomes, five (8.6%) colorectal cancers (CRC) were diagnosed, 23 (39.6%) were persistent non-attendees, 16 (27.5%) had benign colorectal pathology, two (3.4%) benign non-colorectal outcomes and 12 (20.6%) normal outcomes.
  • Care needs to be exercised in the management of FTAs to avoid delayed presentation of colorectal cancer.
  • [MeSH-major] Ambulatory Care / utilization. Colorectal Neoplasms / therapy. Treatment Refusal / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Postgrad Med J. 2001 Jan;77(903):37-9 [11123393.001]
  • [Cites] J Paediatr Child Health. 2002 Feb;38(1):79-83 [11869406.001]
  • [Cites] J R Soc Med. 2002 Sep;95(9):448-9 [12205209.001]
  • [Cites] Aust Health Rev. 2003;26(1):52-63 [15485374.001]
  • [Cites] Soc Sci Med. 1988;27(6):651-60 [3227371.001]
  • [Cites] Arch Dis Child. 1997 Nov;77(5):423-6 [9487966.001]
  • [Cites] J R Soc Med. 1999 Mar;92(3):114-8 [10396253.001]
  • [Cites] Endoscopy. 2004 May;36(5):402-4 [15100947.001]
  • (PMID = 17688719.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2048594
  •  go-up   go-down


59. Huang Z, Li L, Wang J: Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci; 2007 Sep;52(9):2287-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions.
  • DNA methylation is a key mechanism of colorectal carcinogenesis.
  • Analysis of aberrantly methylation in stool DNA might provide a novel strategy for noninvasive detection of colorectal cancer (CRC).
  • To explore the feasibility of this approach, we have assessed the methylation status of secreted frizzled-related protein gene 2 (SFRP2) in stool samples from patients with CRC with respect to a series of healthy individuals and patients with benign colorectal diseases, using methylation-specific polymerase chain reaction.
  • Methylation testing of fecal DNA may be a simple, promising, and noninvasive screening tool for colorectal neoplasia.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colorectal Neoplasms. DNA Methylation. DNA, Neoplasm / analysis. Feces / chemistry. Membrane Proteins / genetics. Precancerous Conditions
  • [MeSH-minor] Apoptosis. Biopsy. Colonoscopy. Diagnosis, Differential. Disease Progression. Humans. Polymerase Chain Reaction. Prognosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis Sci. 2005 Nov;50(11):2147-52 [16240230.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):858-65 [11390535.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):142-9 [15704048.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1495-501 [15342451.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):29-39 [15000147.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Clin Chem. 2004 Nov;50(11):2179-82 [15502094.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Gut. 2004 Apr;53(4):573-80 [15016754.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1219-27 [11054379.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] Clin Colorectal Cancer. 2003 May;3(1):47-53 [12777192.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • (PMID = 17410438.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Membrane Proteins; 0 / SFRP2 protein, human
  •  go-up   go-down


60. Waldby G, Ryan JJ: Screening for colorectal cancer. S D Med; 2010 May;63(5):175-7
Hazardous Substances Data Bank. Barium sulfate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for colorectal cancer.
  • Screening can lead to the early diagnosis of specific cancers which, when treated, can result in a prolonged life span.
  • Colorectal cancer is the third-most common form of cancer in the Western world.
  • The specific advantage of colorectal cancer screening include the earlier detection of such cancers, the detection of benign conditions such as polyps that can predispose to cancer and the potential for earlier and curative therapy in these patients.
  • Screening for colorectal cancer is indicated where life expectantly is greater then five years and, in general, for people under 75 years of age.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Mass Screening. Precancerous Conditions / diagnosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20462062.001).
  • [ISSN] 0038-3317
  • [Journal-full-title] South Dakota medicine : the journal of the South Dakota State Medical Association
  • [ISO-abbreviation] S D Med
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


61. Hassan I, You YN, Cima RR, Larson DW, Dozois EJ, Barnes SA, Pemberton JH: Hand-assisted versus laparoscopic-assisted colorectal surgery: Practice patterns and clinical outcomes in a minimally-invasive colorectal practice. Surg Endosc; 2008 Mar;22(3):739-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hand-assisted versus laparoscopic-assisted colorectal surgery: Practice patterns and clinical outcomes in a minimally-invasive colorectal practice.
  • We investigated the patient selection and short-term clinical outcomes of HALS and LA since the introduction of HALS to our minimally invasive colorectal practice.
  • RESULTS: HALS patients were similar to LA patients in age (51 vs. 54 yrs), gender (56 vs. 52% male), body mass index (26 vs. 26 kg/m2), comorbidities (84 vs. 85% with one or more), and diagnosis (83 vs. 80% benign), but differed in incidence of previous surgery (49 vs. 30%; P = 0.008).
  • [MeSH-major] Colectomy / instrumentation. Colonoscopy / methods. Colorectal Neoplasms / surgery. Minimally Invasive Surgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Colorectal Surgery / methods. Female. Follow-Up Studies. Hand. Humans. Length of Stay. Male. Middle Aged. Pain, Postoperative / physiopathology. Postoperative Care / methods. Postoperative Complications / physiopathology. Probability. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Rate

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2007 Feb;204(2):291-307 [17254934.001]
  • [Cites] Dis Colon Rectum. 2004 May;47(5):753-65 [15073660.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):984-91; discussion 991-2 [15570204.001]
  • [Cites] Surg Endosc. 2004 Apr;18(4):577-81 [15026923.001]
  • [Cites] Surg Endosc. 2007 Feb;21(2):234-7 [17160652.001]
  • [Cites] Dis Colon Rectum. 2006 Apr;49(4):464-9 [16518715.001]
  • [Cites] Surg Endosc. 2006 Jul;20(7):1077-82 [16736305.001]
  • [Cites] Surg Endosc. 2004 Apr;18(4):582-6 [15026921.001]
  • [Cites] Surg Endosc. 2004 Jan;18(1):102-5 [12958676.001]
  • [Cites] Surg Endosc. 2005 May;19(5):656-61 [15776212.001]
  • [Cites] J Gastrointest Surg. 2006 Dec;10(10):1330-6; discussion 1336-7 [17175451.001]
  • [Cites] Ann Surg. 2006 May;243(5):667-70; discussion 670-2 [16633002.001]
  • [Cites] Surg Endosc. 2000 Oct;14(10):896-901 [11080399.001]
  • [Cites] Surg Endosc. 2001 Nov;15(11):1277-81 [11727133.001]
  • [Cites] Surg Endosc. 2000 Oct;14(10):891-5 [11080398.001]
  • [Cites] Surg Endosc. 2004 Mar;18(3):397-401 [14735341.001]
  • [Cites] Surg Endosc. 2000 Nov;14(11):999-1004 [11116405.001]
  • [Cites] Dis Colon Rectum. 2005 Oct;48(10):1845-50 [16175324.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):975-81 [15793638.001]
  • [Cites] Ann Surg. 2000 May;231(5):715-23 [10767793.001]
  • (PMID = 17704883.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


62. Bertelsen CA, Meisner S, West F, Wille-Jørgensen PA: [Treatment of colorectal obstruction with self-expanding metal stents]. Ugeskr Laeger; 2006 Feb 27;168(9):907-11
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of colorectal obstruction with self-expanding metal stents].
  • INTRODUCTION: Self-expanding metal stents (SEMS) serve as a bridge to surgery in cases of acute colorectal obstruction and provide palliation without surgery in patients with severe co-morbidity or disseminated disease.
  • We describe our experiences with the use of SEMS in colorectal obstruction.
  • In 11 patients the stricture was caused by benign pathology.
  • In 11 cases of benign strictures, only 4 were successful.
  • CONCLUSION: SEMS is a safe, effective procedure in the treatment of colorectal obstruction.
  • In our experience, stenting of benign strictures is ineffective and associated with higher rates of complications.
  • [MeSH-major] Colonic Diseases / therapy. Colorectal Neoplasms / therapy. Intestinal Obstruction / therapy. Rectal Diseases / therapy. Stents


63. Hodder RJ, Ballal M, Selvachandran SN, Cade D: Variations in the evaluation of colorectal cancer risk. Colorectal Dis; 2005 May;7(3):254-62
Hazardous Substances Data Bank. Barium sulfate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations in the evaluation of colorectal cancer risk.
  • SUBJECTS AND METHODS: Forty-three clinicians were each asked to assess 40 symptomatic colorectal referrals.
  • RESULTS: There was a wide degree of variation among all clinicians grading both benign and malignant disease with the overall correct classification of 54% (P-value of <0.001).
  • On average, the clinicians correctly diagnosed 71.3% of the cancer patients as compared to 44% of the benign patients.
  • Of the cancer patients, 47% were correctly classified as an urgent referral whilst 52% of the benign patients were over classified and graded as an urgent referral.
  • The mean number chosen by clinicians to have a flexible sigmoidoscopy as the appropriate first investigation was 13 (of 40 patients); this was despite the diagnosis being possible in all cases with a flexible sigmoidoscopy.
  • [MeSH-major] Carcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Practice Patterns, Physicians'. Referral and Consultation / standards

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859964.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


64. Tsafrir D, Bacolod M, Selvanayagam Z, Tsafrir I, Shia J, Zeng Z, Liu H, Krier C, Stengel RF, Barany F, Gerald WL, Paty PB, Domany E, Notterman DA: Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res; 2006 Feb 15;66(4):2129-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of gene expression and chromosomal abnormalities in colorectal cancer.
  • In this work, three types of array-generated data (expression, single nucleotide polymorphism, and comparative genomic hybridization) were collected from a large set of colon cancer patients at various stages of the disease.
  • We show that across many large regions of the genome, changes in expression level are correlated with alterations in DNA content.
  • Often, large chromosomal segments, containing multiple genes, are transcriptionally affected in a coordinated way, and we show that the underlying mechanism is a corresponding change in DNA content.
  • Indeed, particular chromosomal regions are frequently gained and overexpressed (e.g., 7p, 8q, 13q, and 20q) or lost and underexpressed (e.g., 1p, 4, 5q, 8p, 14q, 15q, and 18) in primary colon tumors, making it likely that these changes favor tumorigenicity.
  • Furthermore, we show that these aberrations are absent in normal colon mucosa, appear in benign adenomas (albeit only in a small fraction of the samples), become more frequent as disease advances, and are found in the majority of metastatic samples.
  • [MeSH-major] Chromosome Aberrations. Colorectal Neoplasms / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Chromosomes, Human, Pair 20 / genetics. DNA, Neoplasm / genetics. Gene Dosage. Gene Expression Profiling. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16489013.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA65930
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


65. Paschos KA, Canovas D, Bird NC: The engagement of selectins and their ligands in colorectal cancer liver metastases. J Cell Mol Med; 2010 Jan;14(1-2):165-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The engagement of selectins and their ligands in colorectal cancer liver metastases.
  • he colonization of the liver by colorectal cancer (CRC) cells is a complicated process which includes many stages, until macrometastases occur.
  • The three members of the selectin family, E-, P- and L-selectin, in conjunction with sialylated Lewis ligands and CD44 variants, regulate colorectal cell communication and adhesion with platelets, leucocytes, sinusoidal endothelial cells and stellate cells.
  • Therefore, trials have already commenced aiming to exploit selectins and their ligands in the treatment of benign and malignant diseases.
  • [MeSH-major] Colorectal Neoplasms. Ligands. Liver Neoplasms. Protein Isoforms / metabolism. Selectins / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19627399.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Hexanes; 0 / Ligands; 0 / Protein Isoforms; 0 / Selectins; 0 / sialyl Lewis X antigen; 97B5KCW80W / bimosiamose; PHA4727WTP / Mannose
  • [Number-of-references] 122
  • [Other-IDs] NLM/ PMC3837616
  •  go-up   go-down


66. Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, Zhu RM, Li GL, Xia XY, Wei XW, Ji HZ, Lu H, Gao Y, Gao WM, Chen LB: Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol; 2008 May 21;14(19):3074-80
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.
  • AIM: To evaluate the diagnostic role of serum RASSF1A promoter hypermethylation in gastric and colorectal adenocarcinoma.
  • METHODS: Methylation-specific polymerase chain reaction (MSPCR) was used to examine the promoter methylation status of the serum RASSF1A gene in 47 gastric adenocarcinoma patients, 45 colorectal adenocarcinoma patients, 60 patients with benign gastrointestinal disease (30 with benign gastric disease and 30 with benign colorectal disease), and 30 healthy donor controls.
  • A paired study of RASSF1A promoter methylation status in primary tumor, adjacent normal tissue, and postoperative serum were conducted in 25 gastric and colorectal adenocarcinoma patients who later were underwent surgical therapy.
  • RESULTS: The frequencies of detection of serum RASSF1A promoter hypermethylation in gastric (34.0%) and colorectal (28.9%) adenocarcinoma patients were significantly higher than those in patients with benign gastric (3.3%) or colorectal (6.7%) disease or in healthy donors (0%) (P < 0.01).
  • The methylation status of RASSF1A promoter in serum samples was consistent with that in paired primary tumors, and the MSPCR results for RASSF1A promoter methylation status in paired preoperative samples were consistent with those in postoperative serum samples.
  • The serum RASSF1A promoter hypermethylation did not correlate with patient sex, age, tumor differentiation grade, surgical therapy, or serum carcinoembryonic antigen level.
  • CONCLUSION: Aberrant CpG island methylation within the promoter region of RASSF1A is a promising biomarker for gastric and colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / blood. Promoter Regions, Genetic. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2000 Dec;30(3):211-4 [11147802.001]
  • [Cites] Oncol Rep. 2007 Nov;18(5):1225-30 [17914577.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7034-8 [11585730.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(12):4309-18 [12024041.001]
  • [Cites] Oncogene. 2002 May 23;21(23):3792-5 [12032847.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1761-6 [12060614.001]
  • [Cites] Oncogene. 2002 Oct 17;21(47):7277-82 [12370819.001]
  • [Cites] Int J Cancer. 2002 Dec 20;102(6):623-8 [12448005.001]
  • [Cites] J Pathol. 2003 May;200(1):23-31 [12692837.001]
  • [Cites] Cancer Lett. 2003 Apr 25;193(2):207-16 [12706879.001]
  • [Cites] Cancer Lett. 2003 May 8;194(1):99-105 [12706863.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8125-36 [14603253.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):96-100 [15185349.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4244-50 [15205337.001]
  • [Cites] Cancer Res. 1977 Mar;37(3):646-50 [837366.001]
  • [Cites] Oncology. 1989;46(5):318-22 [2779946.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5):556-60 [10528904.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3441-54 [15526363.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1219-25 [15709192.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1141-5 [15734995.001]
  • [Cites] Histol Histopathol. 2005 Apr;20(2):645-63 [15736067.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3682-90 [15867363.001]
  • [Cites] Biochemistry (Mosc). 2005 May;70(5):576-83 [15948711.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1293-6 [16001680.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5205-10 [16051962.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7653-9 [16140931.001]
  • [Cites] Oncogene. 2005 Nov 17;24(51):7630-4 [16007118.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):339-46 [16139926.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):315-9 [10888881.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):35669-72 [10998413.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):192-8 [16482617.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):4557-63 [16344548.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Lung Cancer. 2007 May;56(2):289-94 [17267069.001]
  • [Cites] BMC Cancer. 2007;7:120 [17608924.001]
  • [Cites] Int J Surg Pathol. 2007 Jul;15(3):242-51 [17652530.001]
  • [Cites] J Cell Sci. 2007 Sep 15;120(Pt 18):3163-72 [17878233.001]
  • [Cites] Mol Cell. 2007 Sep 21;27(6):962-75 [17889669.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]
  • (PMID = 18494062.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2712178
  •  go-up   go-down


67. Ji BT, Weissfeld JL, Chow WH, Huang WY, Schoen RE, Hayes RB: Tobacco smoking and colorectal hyperplastic and adenomatous polyps. Cancer Epidemiol Biomarkers Prev; 2006 May;15(5):897-901
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tobacco smoking and colorectal hyperplastic and adenomatous polyps.
  • Colorectal adenomas and possibly some hyperplastic polyps are precursors of colorectal cancer.
  • Tobacco use is associated in epidemiologic studies with these polyps, although links between smoking and colorectal cancer are less consistent.
  • To characterize the role of tobacco in early colorectal carcinogenesis, we compared tobacco use among 4,383 subjects with histologically verified benign (hyperplastic or adenomatous) polyps of the distal colon (descending colon, sigmoid, and rectum) with tobacco use among 33,667 subjects who were endoscopy negative for distal colon tumors, in the screening arm of the Prostate, Lung, Colorectal, and Ovarian Trial, a randomized trial of flexible sigmoidoscopy.
  • [MeSH-major] Adenomatous Polyposis Coli / etiology. Colorectal Neoplasms / etiology. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702367.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


68. Olesen SH, Christensen LL, Sørensen FB, Cabezón T, Laurberg S, Orntoft TF, Birkenkamp-Demtröder K: Human FK506 binding protein 65 is associated with colorectal cancer. Mol Cell Proteomics; 2005 Apr;4(4):534-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human FK506 binding protein 65 is associated with colorectal cancer.
  • We initiated the present study to identify new genes associated with colorectal cancer.
  • In a previously published microarray study an EST (W80763), later identified as the gene hFKBP10 (NM_021939), was found to be strongly expressed in tumors while absent in the normal mucosa.
  • Here we describe this gene hFKBP10 together with its encoded protein hFKBP65 as a novel marker associated with colorectal cancer.
  • Analysis of 31 colorectal adenocarcinomas and 14 normal colorectal mucosa by RealTime PCR for hFKBP10 showed a significant up-regulation in tumors, when compared with normal mucosa.
  • Immunohistochemical analysis of 26 adenocarcinomas and matching normal mucosa, as well as benign hyperplastic polyps and adenomas, using a monoclonal anti-hFKBP65 antibody, showed that the protein was not present in normal colorectal epithelial cells, but strongly expressed in the tumor cells of colorectal cancer.
  • The protein was also expressed in fibroblasts of both normal mucosa and tumor tissue.
  • Western blot analysis of matched tumors and normal mucosa supported the finding of increased hFKBP65 expression in tumors compared with normal mucosa, in addition to identifying the molecular mass of hFKBP65 to approximately 72 kDa.
  • In conclusion, the protein hFKBP65 is associated with colorectal cancer, and we hypothesize the protein to be involved in fibroblast and transformed epithelial cell-specific protein synthesis in the endoplasmic reticulum.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Tacrolimus Binding Proteins / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671042.001).
  • [ISSN] 1535-9476
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; EC 5.2.1.- / Tacrolimus Binding Proteins
  •  go-up   go-down


69. Betambeau N, Simson JN: Staged anterior resection and TEM to preserve rectal function in synchronous malignant and benign rectal lesions. Colorectal Dis; 2007 Jun;9(5):469-71
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staged anterior resection and TEM to preserve rectal function in synchronous malignant and benign rectal lesions.
  • BACKGROUND: Traditionally patients with a high rectosigmoid carcinoma and a synchronous large distal rectal adenoma would be treated by low anterior resection with associated loss of rectal function.
  • Preoperative and postoperative rectal function was assessed using the St. Mark's incontinence score.
  • [MeSH-major] Adenoma / surgery. Carcinoma / surgery. Endoscopy / methods. Neoplasms, Multiple Primary / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504346.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


70. Cui M, Wang S, Ye YJ, Cui ZR, Ke Y: [Effect of tumor burden on differentiation of T lymphocytes in the peripheral blood of patients with colorectal cancer]. Zhonghua Yi Xue Za Zhi; 2007 Jan 2;87(1):16-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of tumor burden on differentiation of T lymphocytes in the peripheral blood of patients with colorectal cancer].
  • OBJECTIVE: To analyze the effect of tumor burden on the differentiation of T1 and T2 cells and its implication in patients with colorectal cancer.
  • METHODS: Peripheral venous blood samples were obtained from 20 patients with primary colorectal cancer before and 7 days after the operation, radical operation in 17 patients and palliative resection in 3 patients.
  • Twenty sex and age-matched patients with benign diseases treated in the same period were used as controls.
  • RESULTS: At the time of diagnosis, the percentage of T1 and T2 cells in the peripheral lymphocytes of the case group was lower significantly than that of the control group (P = 0.006, and P = 0.017).
  • After getting rid of the tumor burden, the percentage of T1 cells increased, however, not significantly (P > 0.05).
  • The percentages of T1 cell of the patients with the tumor > or = 5 cm and of the patients with poorly differentiated tumors were significantly lower than those of the patients with the tumor < 5 cm and of the patients with well or moderately differentiated tumors (P = 0.064, and P = 0.072).
  • The percentage of T1 cells in the patients with lymph node metastasis and stage III approximately IV tumor were lower significantly than those of the patients without lymph node metastasis and those with stage I approximately II tumor (P = 0.033 and P = 0.033).
  • No significant differences were found between the population of T1 cells and such factors as tumor size, serosa invasion, and distant metastasis.
  • CONCLUSION: Tumor load suppresses the differentiation of T1 and T2 cells in the patients with colorectal cancer significantly, and may be an important factor in the development of immunosuppression.
  • After getting rid of the tumor burden, the percentages of T1 and T2 increase in a short time, and the immunologic function is improved.
  • Determination of T1 may be helpful to indicate the prognosis of colorectal cancer.
  • [MeSH-major] Cell Differentiation / immunology. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology. T-Lymphocytes / cytology
  • [MeSH-minor] Aged. CD4-Positive T-Lymphocytes / cytology. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / cytology. CD8-Positive T-Lymphocytes / immunology. Female. Flow Cytometry. Humans. Killer Cells, Natural / cytology. Killer Cells, Natural / immunology. Male. Middle Aged. Neoplasm Staging. Tumor Burden

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403305.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


71. Hewitt MJ, Wood N, Quinton ND, Charlton R, Taylor G, Sheridan E, Duffy SR: The detection of microsatellite instability in blind endometrial samples--a potential novel screening tool for endometrial cancer in women from hereditary nonpolyposis colorectal cancer families? Int J Gynecol Cancer; 2006 May-Jun;16(3):1393-400
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The detection of microsatellite instability in blind endometrial samples--a potential novel screening tool for endometrial cancer in women from hereditary nonpolyposis colorectal cancer families?
  • Microsatellite instability (MSI) is the phenotypic molecular characteristic of the majority of tumors associated with the hereditary nonpolyposis colorectal cancer syndrome (HNPCC).
  • Twenty-four women with EC, 20 women from HNPCC kindreds, and 20 women undergoing gynecological surgery for benign indications underwent blind sampling.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Genomic Instability. Microsatellite Repeats
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / pathology. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / pathology. Family Health. Female. Humans. Middle Aged. Molecular Diagnostic Techniques / methods. Single-Blind Method

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803536.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Qiu MZ, Yuan ZY, Luo HY, Ruan DY, Wang ZQ, Wang FH, Li YH, Xu RH: Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumour Biol; 2010 Aug;31(4):255-60
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of pretreatment hematologic profile on survival of colorectal cancer patients.
  • Pretreatment hematologic abnormalities have been reported to have prognostic value in patients with solid tumors.
  • The aim of our study was to determine the prevalence of abnormalities in the hematologic profile in patients with colorectal cancer before treatment and to evaluate if such a profile could be used for prognostic evaluations.
  • We identified all patients in Cancer Center of Sun Yat-Sen University who were diagnosed as colorectal cancers between May 2005 and August 2009.
  • We identified 363 patients with colorectal cancer and 315 patients with benign diseases for the final analysis.
  • The percentages of leukocytosis, anemia, and thrombocytosis were significantly higher in colorectal cancer patients than in patients with benign diseases.
  • Univariate analysis showed that advanced tumor stages, leukocytosis, anemia, thrombocytosis, and low histological grade were all significantly associated with shorter survival.
  • The multivariate Cox analysis revealed that low histological grade, tumor stage, pretreatment anemia, and thrombocytosis remained independent prognostic variables for survival.
  • Anemia and thrombocytosis can be considered as useful prognostic markers in patients with colorectal cancer.
  • [MeSH-major] Anemia / diagnosis. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Leukocytosis / diagnosis. Thrombocytosis / diagnosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tex Med. 1990 Oct;86(10):80-3 [2247849.001]
  • [Cites] Clin Otolaryngol. 2008 Jun;33(3):245-51 [18559031.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2214-21 [11413508.001]
  • [Cites] Thromb Haemost. 2003 Jun;89(6):1098-106 [12783124.001]
  • [Cites] Eur Respir J. 1996 Sep;9(9):1826-30 [8880098.001]
  • [Cites] Thromb Haemost. 1998 May;79(5):916-8 [9609220.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):988-9 [15879160.001]
  • [Cites] Oncology. 2000 Feb;58(2):169-74 [10705245.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2399-405 [11745296.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1740-6 [15742330.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):2-6 [9671322.001]
  • [Cites] Urology. 2004 Mar;63(3):447-50 [15028435.001]
  • [Cites] Thromb Haemost. 1990 Dec 28;64(4):501-5 [1964750.001]
  • [Cites] Tumour Biol. 2000 Sep-Oct;21(5):309-14 [10940827.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):211-4 [14751160.001]
  • [Cites] J Am Coll Surg. 2004 May;198(5):737-41 [15110807.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):778-87 [12788185.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Dec;135(12):1783-90 [19551407.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):208-12 [17368603.001]
  • [Cites] JAMA. 1982 Feb 19;247(7):1004-6 [7035703.001]
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):287-91 [11923136.001]
  • [Cites] J Cell Mol Med. 2009 Mar;13(3):555-61 [18429933.001]
  • [Cites] J Clin Epidemiol. 1996 Dec;49(12):1373-9 [8970487.001]
  • [Cites] Oral Oncol. 2007 Mar;43(3):283-8 [16920387.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):335-42 [17504931.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):847-53 [15143932.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10 (3):295-305 [18297062.001]
  • (PMID = 20336401.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Gao Y, Zhang B: [Expression of TEIF protein in colorectal tumors and its correlation with centrosome abnormality]. Ai Zheng; 2009 Dec;28(12):1277-82
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of TEIF protein in colorectal tumors and its correlation with centrosome abnormality].
  • BACKGROUND AND OBJECTIVE: Telomerase transcriptional elements-interacting factor (TEIF) gene found recently by our research group is a transcription factor of a kind of human telomerase reverse transcriptase (hTERT) gene, and expresses in many kinds of tumor tissues.
  • This study was to evaluate the expression of TEIF protein in human colorectal tumors and to explore its correlation with centrosome abnormality.
  • METHODS: The expression of TEIF in 10 specimens of normal intestinal mucosa tissue, 30 specimens of colorectal cancer, and 54 specimens of colorectal adenoma was detected by immunohistochemistry.
  • RESULTS: Immunohistochemistry results showed that the differences of TEIF protein expression between the normal group and each tumor groups were statistically significant (P<0.01), and the difference of TEIF protein expression between the malignant tumor group and the benign group was not significant (P>0.05).
  • Immunofluorescence results showed that centrosome amplification-positive rate was significantly higher in the colorectal cancer group than in the normal group or the adenoma group (both P<0.01); the difference of the centrosome amplification positive rate between Grade I adenoma and Grade III adenoma was statistically significant (P<0.05), and the differences of the centrosome amplification positive rate between Grade II adenoma and Grade I or III adenoma were statistically significant (P>0.05).
  • CONCLUSIONS: TEIF protein and centrosome amplification is commonly found in colorectal tumors.
  • The expression level of TEIF is related to tumor histological grade and malignant degree.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Centrosome / pathology. Colorectal Neoplasms / metabolism. Transcription Factors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958622.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Transcription Factors; 0 / Tubulin; EC 2.7.1.- / SCYL1 protein, human
  •  go-up   go-down


74. Sajid MS, Rimpel J, Iftikhar M, Baig MK: Use of health related quality of life tools in colorectal surgery. Acta Chir Belg; 2007 Nov-Dec;107(6):623-9
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of health related quality of life tools in colorectal surgery.
  • OBJECTIVE: The objective of this article is to discuss the various tools used in colorectal surgery for the measurement of health related quality of life (HR-QOL) and highlight various outcome variables that affect the HR-QOL.
  • METHODS: Review of HR-QOL articles published on various colorectal procedures in last 25 years.
  • These HR-QOL tools are very helpful for the evaluation of subjective outcome of common colorectal procedures.
  • Gastrointestinal Quality of Life Index (GIQLI) for benign anorectal conditions, European Organization for the Research and Treatment of Cancer (EORTC QLQ-C30), EORTC QLQ-CR38 and Functional Assessment of Cancer Therapy-Colorectal (FACT-C) for colorectal cancer and Inflammatory Bowel Disease Questionnaire (IBDQ) for all types of inflammatory bowel disease are being used frequently to assess the quality of life after surgery.
  • CONCLUSION: The use of validated and reliable health instruments in colorectal surgery is directed at measuring the impact in a reproducible and valid fashion.
  • Curative or palliative procedures should be offered to the patients of colorectal disorders after the assessment by HR-QOL tools.
  • [MeSH-minor] Colonic Neoplasms / surgery. Colonic Pouches. Digestive System Surgical Procedures. Humans. Inflammatory Bowel Diseases / surgery. Laparoscopy. Neoplasm Recurrence, Local / surgery. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18274174.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 77
  •  go-up   go-down


75. Galitskiĭ MV, Khomeriki SG, Nikiforov PA: [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy]. Eksp Klin Gastroenterol; 2009;(5):28-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy].
  • The cholecystectomy results in change of cholic acids flow into intestine.
  • Permanent type of the bile flow provokes the increase of proliferation of colic epithelial cells and increases the risk for development of right-sided colorectal tumors.
  • Meanwhile morphological features of colorectal tumors at the patients with cholecystectomy are still remaining to be clarified.
  • The goal of the study was to investigate immunohistochemical markers of proliferation and apoptosis in colorectal adenomas and adenocarcinomas at the patients with cholecystectomy.
  • 83 tumors and 49 samples of mucosa were immunostained with monoclonal mouse anti-human p53 protein (Dako) and monoclonal mouse anti-human Ki-67 antigen (Novocastra).
  • Thus, in benign colorectal tumors at the patients with retained function of gallbladder intensifying of epithelial cells proliferation is not accompanied with intensifying of apoptosis, and in malignant tumors a complete supression of apoptosis is observed.
  • The retaining of apoptosis in colorectal tumors compensates intensive proliferative activity with expectation of better prognosis.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / biosynthesis. Cell Proliferation. Cholecystectomy. Colon / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Intestinal Mucosa / metabolism. Ki-67 Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205327.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


76. Nocito A, Hahnloser D: [Indications for laparoscopic colorectal resections--also for cancers?]. Ther Umsch; 2005 Feb;62(2):119-26
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indications for laparoscopic colorectal resections--also for cancers?].
  • Laparoscopic procedures are applied to the treatment of almost all colonic diseases, including both benign and malignant lesions.
  • Significant benefits can be expected with a laparoscopic approach relative to decreased pain, ileus, length of hospital stay, disability, and possibly, adhesion formation and subsequent bowel obstruction, and improved cosmesis.
  • However, all those benefits are secondary in the treatment of cancer; tumor-free survival must be the primary goal.
  • Laparoscopic colorectal surgery for cancer will have a definite role in the future.
  • [MeSH-major] Colectomy / methods. Colonic Diseases / surgery. Colorectal Neoplasms / surgery. Laparoscopy. Rectal Diseases / surgery

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756922.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 73
  •  go-up   go-down


77. Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C: Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology; 2010 Dec;139(6):1927-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers.
  • The association of benign and malignant GI neoplasias with CS remains debatable.
  • Nine (13%) subjects had colorectal cancer, all younger than the age of 50.
  • CONCLUSIONS: PTEN-associated CS should be considered a mixed polyp syndrome, with hyperplastic polyps most prevalent, with a risk of early onset colorectal cancer.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Clin Endocrinol Metab. 2000 Jun;85(6):2334-8 [10852473.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2009 Mar;6(3):184-9 [19190598.001]
  • [Cites] J Med Genet. 2000 Nov;37(11):828-30 [11073535.001]
  • [Cites] Am J Hum Genet. 2003 Aug;73(2):404-11 [12844284.001]
  • [Cites] Br J Dermatol. 1975 Sep;93(3):329-36 [1191539.001]
  • [Cites] J Am Acad Dermatol. 1983 May;8(5):686-96 [6863628.001]
  • [Cites] Am J Surg Pathol. 1984 Oct;8(10):763-70 [6496844.001]
  • [Cites] Clin Genet. 1986 Mar;29(3):222-33 [3698331.001]
  • [Cites] J Am Acad Dermatol. 1986 Aug;15(2 Pt 1):294-6 [3745534.001]
  • [Cites] J Clin Gastroenterol. 1986 Oct;8(5):576-9 [3782758.001]
  • [Cites] Gastrointest Radiol. 1987;12(4):325-9 [3040507.001]
  • [Cites] J Clin Gastroenterol. 1994 Jan;18(1):42-7 [8113585.001]
  • [Cites] J Med Genet. 1995 Feb;32(2):117-9 [7760320.001]
  • [Cites] Surgery. 1995 Jul;118(1):115-7 [7604372.001]
  • [Cites] Nat Genet. 1996 May;13(1):114-6 [8673088.001]
  • [Cites] Int J Oncol. 1998 Mar;12(3):701-10 [9472113.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):476-90 [15667510.001]
  • [Cites] JAMA. 2005 Nov 16;294(19):2465-73 [16287957.001]
  • [Cites] Int J Mol Med. 2006 Oct;18(4):643-7 [16964417.001]
  • [Cites] Nat Rev Cancer. 2007 Jan;7(1):35-45 [17167516.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2007 Sep;4(9):492-502 [17768394.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3147-51 [10866302.001]
  • (PMID = 20600018.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA124570; United States / NCI NIH HHS / CA / P01CA124570
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ NIHMS466893; NLM/ PMC3652614
  •  go-up   go-down


78. Erdas E, Zedda A, Pitzalis A, Scano D, Barbarossa M, Aresu S, Licheri S, Pomata M, Farina G: [Anastomotic leak following colorectal surgery: incidence, risk factors and treatment]. Chir Ital; 2009 Jul-Aug;61(4):407-17
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anastomotic leak following colorectal surgery: incidence, risk factors and treatment].
  • The aim of this study was to assess the incidence and identify the risk factors associated with colorectal anastomotic leakage.
  • We reviewed the clinical files of 124 patients who underwent mechanical end-to-end anastomosis after colorectal resection during the period 2000-2007.
  • Indications for surgery were malignant neoplasms in 109 cases (87.9%) and benign disease in 15 cases (12.1%).
  • The pelvic drain was always effective in allowing the early diagnosis of leakages and limiting the spread of peritoneal inflammation.
  • In conclusion, the study confirms low anastomotic level as a negative prognostic factor for the healing of colorectal anastomosis.
  • The pelvic drain proved to be effective in allowing early diagnosis and conservative management of leakages.
  • [MeSH-major] Colonic Neoplasms / surgery. Postoperative Complications / epidemiology. Postoperative Complications / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19845262.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


79. Qualtrough D, Singh K, Banu N, Paraskeva C, Pignatelli M: The actin-bundling protein fascin is overexpressed in colorectal adenomas and promotes motility in adenoma cells in vitro. Br J Cancer; 2009 Oct 6;101(7):1124-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The actin-bundling protein fascin is overexpressed in colorectal adenomas and promotes motility in adenoma cells in vitro.
  • BACKGROUND: Fascin is overexpressed in many cancers, including colorectal, but its role in the malignant transformation of benign colorectal adenomas is unclear.
  • METHODS: Immunohistochemical analysis of fascin expression was carried out in resected human colorectal adenoma specimens.
  • RESULTS: We show fascin overexpression in adenomas increasing with tumour size, histological type, and degree of dysplasia and increased cell motility in adenoma cell lines following fascin transfection.
  • CONCLUSION: These data suggest an important role for fascin in the malignant progression of colorectal tumours.
  • [MeSH-major] Adenoma / pathology. Carrier Proteins / physiology. Colorectal Neoplasms / pathology. Microfilament Proteins / physiology
  • [MeSH-minor] Cell Line, Tumor. Cell Movement. Disease Progression. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2000 Nov 18;321(7271):1278-81 [11082094.001]
  • [Cites] Int J Cancer. 2007 Aug 15;121(4):734-40 [17437271.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] Cancer Res. 1976 Dec;36(12):4562-9 [1000501.001]
  • [Cites] Int J Cancer. 1984 Jul 15;34(1):49-56 [6746117.001]
  • [Cites] Cancer Res. 1989 Mar 1;49(5):1282-6 [2917357.001]
  • [Cites] Semin Cell Biol. 1994 Jun;5(3):165-74 [7919230.001]
  • [Cites] Lancet. 1996 May 18;347(9012):1377-81 [8637346.001]
  • [Cites] Oncogene. 1997 Jan 23;14(3):283-93 [9018114.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]
  • [Cites] BMC Cancer. 2006;6:241 [17029629.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1118-26 [17375048.001]
  • [Cites] Cell Mol Life Sci. 2001 Mar;58(3):371-92 [11315186.001]
  • (PMID = 19738613.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / FSCN1 protein, human; 0 / Microfilament Proteins
  • [Other-IDs] NLM/ PMC2768091
  •  go-up   go-down


80. Mehigan B, White A, Winter DC, Sheehan KM, Hyland JM: Laparoscopic colorectal resection: initial experience in a specialist unit. Ir Med J; 2006 Jul-Aug;99(7):211, 213-4
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colorectal resection: initial experience in a specialist unit.
  • The adoption of the laparoscopic approach to colorectal resection has been slow amongst colorectal surgeons principally due to concerns regarding oncological safety.
  • Recent randomized controlled trials have confirmed both the safe and some advantage of this procedure have been performing laparoscopic assisted colorectal resection since 2002 and have now performed over 100 cases on non consecutive and selected patients.
  • 61 patients were operated on for cancer and 39 for benign disease mainly Crohn's and diverticular disease.
  • Post operative morbidity and mortality were comparable to open colorectal surgery with the exception of port site herniation which occurred in 4% of patients.
  • This study suggests that a laparoscopic approach to colorectal resection can be successfully introduced in an Irish hospital setting.
  • [MeSH-major] Colectomy. Colorectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16986567.001).
  • [ISSN] 0332-3102
  • [Journal-full-title] Irish medical journal
  • [ISO-abbreviation] Ir Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


81. Holten-Andersen MN, Hansen U, Brünner N, Nielsen HJ, Illemann M, Nielsen BS: Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer; 2005 Jan 10;113(2):198-206
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma.
  • We have previously demonstrated that TIMP-1 is elevated in blood from colorectal cancer patients and that high TIMP-1 levels predict poor prognosis.
  • To clarify the role of TIMP-1 in colorectal tumorigenesis, the expression pattern of TIMP-1 in benign and malignant colorectal tumors was studied.
  • In all of 24 cases of colorectal adenocarcinoma TIMP-1 mRNA was detected by in situ hybridization.
  • No TIMP-1 mRNA was seen in any of the cases in benign or malignant epithelial cells, in vascular cells or smooth muscle cells.
  • In conclusion, TIMP-1 expression is a rare event in benign human colon tissue but is highly expressed by myofibroblasts in association with invading colon cancer cells.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenoma / genetics. Adenoma / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis. Tissue Inhibitor of Metalloproteinase-1 / pharmacology
  • [MeSH-minor] Case-Control Studies. Cell Transformation, Neoplastic. Diagnosis, Differential. Fibroblasts / physiology. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Neoplasm Invasiveness. RNA, Messenger / analysis. RNA, Messenger / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15386409.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1
  •  go-up   go-down


82. Grossmann I, Avenarius JK, Mastboom WJ, Klaase JM: Preoperative staging with chest CT in patients with colorectal carcinoma: not as a routine procedure. Ann Surg Oncol; 2010 Aug;17(8):2045-50
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative staging with chest CT in patients with colorectal carcinoma: not as a routine procedure.
  • BACKGROUND: Preoperative staging of patients with colorectal carcinoma (CRC) has the potential benefit of altering treatment options when metastases are present.
  • MATERIALS AND METHODS: All patients who undergo colorectal surgery in our hospital are prospectively registered, including patient, treatment, and histopathological characteristics; outcome; and follow-up.
  • These were diagnosed during follow-up as true metastases (n = 8), bronchus carcinoma (n = 2), benign lesions (n = 25), and remaining unknown (n = 15).
  • In none of the patients the treatment plan for the primary tumor was changed based on the staging chest CT.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Neoplasm Staging / methods. Preoperative Care. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 2007 Jul-Aug;31(4):569-71 [17882033.001]
  • [Cites] Onkologie. 2007 Mar;30(3):141-5 [17341902.001]
  • [Cites] Ann R Coll Surg Engl. 2007 Nov;89(8):744-8 [17999813.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):1026-32 [19184237.001]
  • [Cites] Colorectal Dis. 2009 Jul;11(6):592-600 [18624816.001]
  • [Cites] Colorectal Dis. 2007 Nov;9(9):816-8 [17931171.001]
  • [Cites] Radiology. 2001 Jan;218(1):55-60 [11152779.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 May;21(5):906-12 [12062285.001]
  • [Cites] Ann Surg Oncol. 1998 Jan-Feb;5(1):9-15 [9524701.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):229-35 [10421258.001]
  • [Cites] Annu Rev Med. 2005;56:139-56 [15660506.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2005 Jan;53(1):22-8 [15724498.001]
  • [Cites] Ann R Coll Surg Engl. 2005 Sep;87(5):331-3 [16176690.001]
  • [Cites] Radiat Med. 2005 Sep;23(6):418-26 [16389984.001]
  • [Cites] Surgery. 2007 Jan;141(1):67-75 [17188169.001]
  • [CommentIn] Ann Surg Oncol. 2011 Dec;18 Suppl 3:S224-5; author reply S226-7 [20839065.001]
  • (PMID = 20151212.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2899025
  •  go-up   go-down


83. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP, National Academy of Clinical Biochemistry: National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem; 2008 Dec;54(12):e11-79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
  • BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed.
  • METHODS: Published reports relevant to use of tumor markers for 5 cancer sites--testicular, prostate, colorectal, breast, and ovarian--were critically reviewed.
  • RESULTS: For testicular cancer, alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. alpha-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors.
  • Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 microg/L.
  • In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease.
  • CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer.
  • CONCLUSIONS: Implementation of these recommendations should encourage optimal use of tumor markers.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. Clinical Laboratory Techniques. Colorectal Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis. Prostatic Neoplasms / diagnosis. Testicular Neoplasms / diagnosis


84. Modarai B, Forshaw M, Parker MC, Stewart M: Self-expanding metallic stents in the treatment of benign colorectal anastomotic strictures: a word of caution. Tech Coloproctol; 2008 Jun;12(2):127-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Self-expanding metallic stents in the treatment of benign colorectal anastomotic strictures: a word of caution.
  • This, to our knowledge, is the first report of a coloenteric fistula developing after insertion of a metallic stent to treat a benign postoperative anastomotic stricture.
  • [MeSH-major] Anastomosis, Surgical / adverse effects. Constriction, Pathologic / therapy. Intestinal Fistula / etiology. Rectal Neoplasms / surgery. Sigmoid Neoplasms / surgery. Stents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):444-50 [14994110.001]
  • [Cites] Am J Surg. 1998 Mar;175(3):194-7 [9560118.001]
  • [Cites] Dis Colon Rectum. 1989 Sep;32(9):733-6 [2667922.001]
  • [Cites] Tech Coloproctol. 2005 Apr;9(1):53-6 [15868501.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1201-7 [15164246.001]
  • [Cites] Colorectal Dis. 2006 Feb;8(2):102-11 [16412069.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1451-60 [14605561.001]
  • [Cites] Cardiovasc Intervent Radiol. 2001 Sep-Oct;24(5):336-9 [11831195.001]
  • [Cites] Gastrointest Endosc Clin N Am. 1999 Jul;9(3):459-77 [10388861.001]
  • [Cites] Radiology. 2002 Jun;223(3):715-22 [12034940.001]
  • [Cites] Gastrointest Endosc. 2000 Sep;52(3):436-8 [10968872.001]
  • [Cites] Gastrointest Endosc. 1998 Mar;47(3):277-86 [9540883.001]
  • (PMID = 18545881.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Metals
  •  go-up   go-down


85. Ferroni P, Roselli M, Spila A, D'Alessandro R, Portarena I, Mariotti S, Palmirotta R, Buonomo O, Petrella G, Guadagni F: Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients. Cancer; 2010 Jun 15;116(12):2913-21
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients.
  • BACKGROUND: This study analyzed the possible prognostic value of presurgical serum soluble (s)E-selectin levels and/or carcinoembryonic antigen (CEA) mRNA positivity in predicting the disease-free survival of colorectal cancer (CRC) patients.
  • METHODS: CEA mRNA (obtained from blood-borne cells by reverse transcriptase-polymerase chain reaction [RT-PCR]), tumor necrosis factor-alpha (TNF-alpha), and sE-selectin levels were analyzed in blood samples obtained from 78 patients with primary (n = 62) or recurrent (n = 16) CRC, 40 patients with benign colorectal (CR) diseases, and 78 controls.
  • Median baseline sE-selectin levels were higher in patients with CRC (43 ng/mL) compared with controls (36 ng/mL) or patients with benign CR diseases (31 ng/mL, P < .001).
  • [MeSH-major] Carcinoembryonic Antigen / genetics. Colorectal Neoplasms / blood. E-Selectin / blood
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. RNA, Messenger / blood. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20336782.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / E-Selectin; 0 / RNA, Messenger
  •  go-up   go-down


86. Horváth HC, Lakatos P, Kósa JP, Bácsi K, Borka K, Bises G, Nittke T, Hershberger PA, Speer G, Kállay E: The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem; 2010 Mar;58(3):277-85
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis.
  • Because 25-hydroxyvitamin D(3) 24-hydroxylase (CYP24A1) is considered to be the main enzyme determining the biological half-life of 1,25-D(3), we have examined expression of the CYP24A1 mRNA (by real-time RT-PCR) and protein (by immunohistochemistry) in normal human colon mucosa, colorectal adenomas, and adenocarcinomas in 111 patients.
  • Although 76% of the normal and benign colonic tissue was either completely devoid of or expressed very low levels of CYP24A1, in the majority of the adenocarcinomas (69%), the enzyme was present at high concentrations.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenoma / enzymology. Biomarkers, Tumor / biosynthesis. Colorectal Neoplasms / enzymology. Steroid Hydroxylases / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biochem. 2000 May;127(5):717-22 [10788778.001]
  • [Cites] Carcinogenesis. 2005 Sep;26(9):1581-9 [15905206.001]
  • [Cites] Eur J Biochem. 2000 Oct;267(20):6158-65 [11012668.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):847-52 [11075874.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):202-8 [11161378.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):888-94 [11158062.001]
  • [Cites] Steroids. 2001 Mar-May;66(3-5):409-22 [11179750.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):1043-51 [11309356.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jul 27;285(4):1012-7 [11467853.001]
  • [Cites] Occup Environ Med. 2002 Apr;59(4):257-62 [11934953.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1583-8 [12352462.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):31-41 [16145679.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):179-94 [16236494.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jan;57(2):234-40 [16180015.001]
  • [Cites] Oncogene. 2006 Mar 2;25(9):1424-33 [16247453.001]
  • [Cites] Future Oncol. 2005 Jun;1(3):415-24 [16556015.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] BMC Cancer. 2006;6:96 [16620391.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4A):2687-99 [16886679.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1819-28 [16708384.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Mar;320(3):1119-26 [17182978.001]
  • [Cites] J Mol Med (Berl). 2007 Mar;85(3):293-304 [17143621.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):684-700 [17721433.001]
  • [Cites] J Histochem Cytochem. 2007 Dec;55(12):1257-64 [17875655.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3131-8 [18089708.001]
  • [Cites] Curr Med Res Opin. 2008 Jan;24(1):139-49 [18034918.001]
  • [Cites] Mol Aspects Med. 2008 Dec;29(6):388-96 [18755215.001]
  • [Cites] Recent Results Cancer Res. 2003;164:239-46 [12899526.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):38084-93 [12867411.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):236-41 [14760115.001]
  • [Cites] J Cutan Pathol. 2004 Mar;31(3):224-31 [14984574.001]
  • [Cites] Lab Invest. 2004 Jun;84(6):693-702 [15077124.001]
  • [Cites] J Histochem Cytochem. 2004 Jul;52(7):985-9 [15208365.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1345-57 [15001537.001]
  • [Cites] Lancet. 1989 Nov 18;2(8673):1176-8 [2572900.001]
  • [Cites] Steroids. 1990 Sep;55(9):395-8 [2281516.001]
  • [Cites] J Biol Chem. 1994 Oct 7;269(40):24673-8 [7929139.001]
  • [Cites] J Invest Dermatol. 1997 Apr;108(4):513-8 [9077483.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 May;62(1):21-8 [9366495.001]
  • [Cites] Endocrinology. 1999 May;140(5):2071-6 [10218956.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):82-90 [10337990.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):481-8 [15718248.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3579-86 [15867263.001]
  • [Cites] J Biol Chem. 2005 May 27;280(21):20604-11 [15788398.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1991-7 [16103450.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jul 14;273(3):977-84 [10891358.001]
  • (PMID = 19901270.001).
  • [ISSN] 1551-5044
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / Receptors, Calcitriol; EC 1.14.- / Steroid Hydroxylases; EC 1.14.13.126 / CYP24A1 protein, human; EC 1.14.13.126 / Vitamin D3 24-Hydroxylase
  • [Other-IDs] NLM/ PMC2825493
  •  go-up   go-down


87. Lim GH, Koh DC, Cheong WK, Wong KS, Tsang CB: Natural history of small, "indeterminate" hepatic lesions in patients with colorectal cancer. Dis Colon Rectum; 2009 Aug;52(8):1487-91
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural history of small, "indeterminate" hepatic lesions in patients with colorectal cancer.
  • PURPOSE: The initial staging CT scan for patients with colorectal cancer may reveal small, "indeterminate" hepatic lesions.
  • The significance of these lesions is often unknown at the time of diagnosis.
  • This study was designed to determine the prevalence and significance of small (<1 cm on CT scan), indeterminate liver lesions detected preoperatively in patients with colorectal cancer and to determine whether further surveillance imaging of these patients is required.
  • All colorectal cancer patients with small, indeterminate liver lesions on their initial staging CT scan were included.
  • RESULTS: Four hundred nineteen patients with colorectal cancer had staging CT performed.
  • Forty-one (89.1%) of these were shown to be stable lesions that were likely benign.
  • CONCLUSION: Small, indeterminate liver lesions may occur in up to 16.7% of patients with colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prevalence. Prognosis. Retrospective Studies. Singapore / epidemiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617765.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Nio Y, Iguchi C, Itakura M, Toga T, Hashimoto K, Koike M, Omori H, Sato Y, Endo S: High incidence of synchronous or metachronous breast cancer in patients with malignant and benign thyroid tumor or tumor-like disorders. Anticancer Res; 2009 May;29(5):1607-10
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of synchronous or metachronous breast cancer in patients with malignant and benign thyroid tumor or tumor-like disorders.
  • In the patients with benign and malignant thyroid tumor or tumor-like disorders, the incidence of other malignancies was surveyed, and the frequency of thyroid cancer in patients with breast cancer was also surveyed.
  • PATIENTS AND METHODS: Between 1982 and 2005, a total of 201 female patients received surgery for tumor or tumor-like disorders, including 65 carcinoma, 68 adenoma, 61 adenomatous goiter and 7 chronic thyroiditis cases.
  • RESULTS: The overall incidence rate of breast cancer was 16.4% (33/201) in the patients, who received thyroid surgeries and was much higher than other malignancies: 2.0% gastric cancer, 1.0% uterine and colorectal cancer.
  • [MeSH-major] Breast Neoplasms / epidemiology. Neoplasms, Second Primary / complications. Thyroid Neoplasms / complications


89. Brosseuk D, Oosthuizen J, Pinchbeck M: Initial experience with a general population colorectal cancer screening clinic. Am J Surg; 2006 May;191(5):669-72
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial experience with a general population colorectal cancer screening clinic.
  • BACKGROUND: Recognition of adenoma to carcinoma progression has established colorectal cancer as a preventable malignancy.
  • Colorectal cancer is, therefore, an ideal malignancy for preventative screening given the presence of a benign precursor.
  • METHODS: A retrospective chart review of all patients referred to a new low-risk colorectal cancer endoscopic screening clinic from October 1, 2004 to September 30, 2005 was performed.
  • Those patients found to have adenomas or carcinomas were analyzed further regarding location of neoplasm and pathologic findings.
  • RESULTS: A total of 379 low-risk patients attended the colorectal cancer screening clinics.
  • Of the 67 patients with neoplasms, 50 were left of the splenic flexure, 11 were right of the splenic flexure, and 5 patients had lesions both proximal and distal to the flexure.
  • Thirty-two of the 67 patients had complete colonoscopy at the initial procedure and, thus far, 21 patients have had completion colonoscopies, of which 9 patients had further neoplasms identified beyond the splenic flexure.
  • All 3 patients with carcinoma had early tumors resected with curative intent, with negative margins and negative nodes.
  • CONCLUSIONS: Our initial experience with a low-risk general population colorectal cancer endoscopic screening clinic yielded 18% of patients with neoplasms, and 1% had curable cancers resected.
  • [MeSH-major] Cancer Care Facilities. Colonoscopy. Colorectal Neoplasms / diagnosis. Mass Screening / methods
  • [MeSH-minor] Aged. Aged, 80 and over. British Columbia / epidemiology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors. Video Recording

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647357.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Votrubova J, Belohlavek O, Jaruskova M, Oliverius M, Lohynska R, Trskova K, Sedlackova E, Lipska L, Stahalova V: The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging; 2006 Jul;33(7):779-84
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of FDG-PET/CT in the detection of recurrent colorectal cancer.
  • PURPOSE: The conventional diagnostic techniques used to assess recurrence of colorectal cancer (CRCR) often yield unspecific findings.
  • Integrated FDG-PET/CT seems to offer promise for the differential diagnosis of benign and malignant lesions.
  • The sensitivity, specificity and accuracy of PET and PET/CT were calculated for (a) intra-abdominal extrahepatic recurrences, (b) extra-abdominal and/or hepatic recurrences and (c) all recurrences, and tumour marker levels were analysed.
  • Two of these cases were due to increased accumulation in inflammatory foci in the bowel wall, while one was due to haemorrhaging into the adrenal gland.
  • CONCLUSION: FDG-PET/CT appears to be a very promising method for distinguishing a viable tumour from fibrous changes, thereby avoiding unnecessary laparotomy.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / surgery. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / prevention & control. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2005 Apr;46(4):587-95 [15809480.001]
  • [Cites] Eur Radiol. 1998;8(5):781-7 [9601965.001]
  • [Cites] Abdom Imaging. 2000 Sep-Oct;25(5):533-41 [10931993.001]
  • [Cites] J Clin Oncol. 1999 Mar;17 (3):894-901 [10071281.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4357-68 [15514377.001]
  • [Cites] Radiol Clin North Am. 2004 Nov;42(6):1123-39, ix [15488562.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1784-8 [14602860.001]
  • [Cites] J Nucl Med. 1997 Aug;38(8):1196-201 [9255148.001]
  • [Cites] Abdom Imaging. 2004 Nov-Dec;29(6):663-8 [15162236.001]
  • [Cites] Radiology. 2004 Aug;232(2):335-46 [15286305.001]
  • [Cites] Radiology. 2004 Sep;232(3):815-22 [15273334.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1797-803 [14602862.001]
  • [Cites] Eur J Nucl Med. 2001 Nov;28(11):1707-23 [11702115.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1078-84 [12195193.001]
  • [Cites] Colorectal Dis. 2003 Sep;5(5):496-500 [12925088.001]
  • [Cites] Radiology. 1989 Feb;170(2):323-8 [2911656.001]
  • (PMID = 16565845.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


91. Kim HJ, Kim KW, Byun JH, Won HJ, Shin YM, Kim PN, Lee MS, Lee MG: Comparison of mangafodipir trisodium- and ferucarbotran-enhanced MRI for detection and characterization of hepatic metastases in colorectal cancer patients. AJR Am J Roentgenol; 2006 Apr;186(4):1059-66
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of mangafodipir trisodium- and ferucarbotran-enhanced MRI for detection and characterization of hepatic metastases in colorectal cancer patients.
  • OBJECTIVE: The purpose of our study was to evaluate the validity of mangafodipir trisodium-enhanced versus ferucarbotran-enhanced MRI in the detection and characterization of hepatic lesions in colorectal cancer patients.
  • MATERIALS AND METHODS: Forty-one patients who were known to have or suspected of having hepatic metastasis from colorectal carcinoma underwent mangafodipir trisodium- or ferucarbotran-enhanced MRI in block randomization methods.
  • Two radiologists independently reviewed the MR images to determine the number of hepatic lesions and to characterize the lesions as malignant or benign.
  • Each lesion was assessed according to its size (small, <or= 2 cm; large, > 2 cm in diameter) on both mangafodipir trisodium- or ferucarbotran-enhanced MRI.
  • The data were correlated with the reference diagnosis: histopathology and intraoperative sonography (n = 16); intraoperative sonography (n = 4); and imaging and clinical diagnosis with follow-up (> 3 months; n = 21).
  • RESULTS: Eighty-two hepatic lesions (53 metastatic and 29 benign) were identified in 41 patients.
  • CONCLUSION: Mangafodipir trisodium- and ferucarbotran-enhanced MRI are similar in hepatic lesion detection and characterization in colorectal cancer patients.
  • [MeSH-major] Colorectal Neoplasms / pathology. Contrast Media. Edetic Acid / analogs & derivatives. Iron. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Magnetic Resonance Imaging / methods. Oxides. Pyridoxal Phosphate / analogs & derivatives

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Iron.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. Ferumoxides .
  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554579.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Magnetite Nanoparticles; 0 / Oxides; 5V5IOJ8338 / Pyridoxal Phosphate; 9G34HU7RV0 / Edetic Acid; E1UOL152H7 / Iron; G6N3J05W84 / ferumoxides; K3R6ZDH4DU / Dextrans; P28BIW0UTB / N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid; XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


92. Piccolo SR, Frey LJ: Somatic mutation signatures of cancer. AMIA Annu Symp Proc; 2008 Nov 06;:202-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The advancement of cancer diagnosis, prognosis, and treatment would be hastened via a robust method to identify patterns that indicate a tumor's state.
  • Prior research has established that sporadic, colorectal-cancer pathogenesis involves a series of genetic mutations that allow benign polyps to develop and eventually progress to malignant tumors in distinguishable patterns.
  • Our results for colorectal cancer are consistent with what extant biological models as described in the literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Pharmacogenomics. 2007 Dec;8(12):1629-33 [18085994.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):318-22 [16421597.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D354-7 [16381885.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):1387-95 [1347643.001]
  • [Cites] N Engl J Med. 2008 Jan 31;358(5):502-11 [18234754.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):769-80 [15510158.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):197-205 [14993901.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):8685-90 [17502601.001]
  • [Cites] Bioinformatics. 2007 Oct 1;23(19):2507-17 [17720704.001]
  • (PMID = 18999255.001).
  • [ISSN] 1942-597X
  • [Journal-full-title] AMIA ... Annual Symposium proceedings. AMIA Symposium
  • [ISO-abbreviation] AMIA Annu Symp Proc
  • [Language] ENG
  • [Grant] United States / NLM NIH HHS / LM / T15 LM007124; United States / NLM NIH HHS / LM / 1T15-LM007124
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2655983
  •  go-up   go-down


93. Pericoli Ridolfini M, Sofo L, Di Giorgio A, Gourgiotis S, Di Miceli D, Alfieri S, Doglietto GB: [Late complication after colon self-expandable metal stent placement: a case report]. Minerva Chir; 2007 Feb;62(1):69-72
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of acute colorectal malignant obstruction, by using self-expandable metallic stents is useful for both palliative and decompressive therapy before the final surgical treatment.
  • In this case, the patient may be benefit from a period of medical optimization prior to undergoing planned surgical resection by a colorectal surgeon.
  • The previous experience in the benign biliary stenosis allowed the extension of using the metallic stents also for the treatment of benign colorectal diseases (diverticular occlusion, anastomotic strictures, colonic endometriosis).
  • The diagnosis was a late rectosigmoid junction perforation by stent placement.
  • [MeSH-minor] Aged, 80 and over. Colorectal Neoplasms / complications. Female. Humans. Time Factors

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287698.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


94. Vibert E, Perniceni T, Levard H, Denet C, Shahri NK, Gayet B: Laparoscopic liver resection. Br J Surg; 2006 Jan;93(1):67-72
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Twenty-four laparoscopic hepatectomies (27 per cent) were for benign disease and 65 (73 per cent) for malignant tumours, including hepatocellular carcinoma (HCC) in 16 patients and colorectal metastasis (CRM) in 41.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Laparoscopy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholecystectomy, Laparoscopic / methods. Colorectal Neoplasms. Disease-Free Survival. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 British Journal of Surgery Society Ltd.
  • (PMID = 16273531.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Rüschoff J, Aust D, Hartmann A: [Colorectal serrated adenoma: diagnostic criteria and clinical implications]. Verh Dtsch Ges Pathol; 2007;91:119-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colorectal serrated adenoma: diagnostic criteria and clinical implications].
  • More than 40 years ago Morson (1962) coined the paradigm that adenomas are the main precursors of colorectal carcinoma (CRC) whereas hyperplastic polyps are "non-neoplastic" lesions without cancer risk.
  • These polyps form the hallmark of a third "serrated (neoplasia) pathway" exhibiting a hyperplastic polyp-like morphology characterized by serrated crypt epithelium.
  • Whereas HPP are benign, SSA are probably slowly progressing lesions and TSA as well as SSA with APC-type adenomatous atypias (iv. mixed SSA) indicate increased cancer risk.
  • [MeSH-major] Adenoma / pathology. Colorectal Neoplasms / pathology
  • [MeSH-minor] Colonic Polyps / pathology. Diagnosis, Differential. Genes, APC. Humans. Hyperplasia / pathology. Mutation


96. Whitehouse PA, Tilney HS, Armitage JN, Simson JN: Transanal endoscopic microsurgery: risk factors for local recurrence of benign rectal adenomas. Colorectal Dis; 2006 Nov;8(9):795-9
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery: risk factors for local recurrence of benign rectal adenomas.
  • OBJECTIVE: Transanal endoscopic microsurgery (TEM) is a minimally invasive technique for excision of selected benign and malignant rectal neoplasms.
  • It is considered a safe and effective treatment but recurrence rates of 1-13% are reported for benign lesions.
  • The aim of this study was to assess risk factors for local recurrence of benign rectal lesions and to evaluate mortality and morbidity following TEM.
  • METHOD: Data were prospectively collected from all patients undergoing TEM for benign adenomas from January 1998 to March 2005.
  • CONCLUSION: TEM is a safe and effective treatment for benign rectal adenomas.
  • [MeSH-major] Adenoma / surgery. Endoscopy / methods. Microsurgery / methods. Neoplasm Recurrence, Local. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2006 Nov;8(9):731-2 [17032317.001]
  • (PMID = 17032328.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Lázár G, Paszt A, Simonka Z, Rokszin R, Abrahám S: [Laparoscopic surgery in colorectal tumors]. Magy Onkol; 2010 Jun;54(2):117-22
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic surgery in colorectal tumors].
  • The minimally invasive technique, by means of the undoubted advantages of the method, has become fully accepted in the surgical treatments of the most benign and functional diseases.
  • Today it has been proven that the laparoscopic technique is safely usable also in the surgical treatment of colorectal tumors.
  • The authors, analyzing their own and the international experiences, present the laparoscopic surgical treatment of colorectal tumors.
  • Seventy-four patients were treated with laparoscopic-assisted colorectal intestinal resection in the Department of Surgery of the University of Szeged between January 1, 2005 and December 31, 2008.
  • The surgical indication was neoplastic colorectal lesion in 40 cases.
  • The histological processes of specimens justified tumor-free oral, aboral and circumferential resection in all cases.
  • Summarizing our own and international experiences it can be stated that the laparoscopic surgeries performed due to colorectal tumors are safe, and are also appropriate with respect to oncosurgery.
  • [MeSH-major] Colorectal Neoplasms / surgery. Digestive System Surgical Procedures / methods. Laparoscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colectomy / methods. Female. Humans. Hungary. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20576587.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


98. Wang Y, Li ZX, An DL, Han JG, Wu JP: [Clinical application of magnifying colonoscopy in diagnosis and treatment of colorectal benign neoplastic lesions]. Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Sep;8(5):416-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical application of magnifying colonoscopy in diagnosis and treatment of colorectal benign neoplastic lesions].
  • OBJECTIVE: To evaluate the clinical value of magnifying endoscopy in diagnosis and treatment of colorectal benign neoplastic lesions.
  • METHODS: Seventy-eight colorectal lesions in 61 patients were examined with magnifying colonoscopy after indigo carmine dyeingìand pit pattern diagnosis was made for every lesion according to Kudos classification to differentiate neoplastic lesions from non-neoplastic lesions.
  • The overall accuracy for adenoma and early colorectal cancer was 96.2%.
  • CONCLUSION: The magnifying colonoscopy can provide instantaneous and accurate diagnosis of neoplastic lesions in colon and rectum,as well as minimally invasive treatment.
  • [MeSH-major] Colonoscopy. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224656.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


99. Smeets P, Ham H, Ceelen W, Boterberg T, Verstraete K, Goethals I: Differentiation between peri-anastomotic inflammatory changes and local recurrence following neoadjuvant radiochemotherapy surgery for colorectal cancer using visual and semiquantitative analysis of PET-CT data. Q J Nucl Med Mol Imaging; 2010 Jun;54(3):327-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between peri-anastomotic inflammatory changes and local recurrence following neoadjuvant radiochemotherapy surgery for colorectal cancer using visual and semiquantitative analysis of PET-CT data.
  • AIM: The aim of this study was to evaluate the usefulness of visual and semiquantitative [¹⁸F]fluorodeoxy-glucose (FDG) positron emission tomography-computed tomography (PET-CT) data for the diagnosis of peri-anastomotic colorectal cancer recurrence, taking into account the time period between surgery and [¹⁸F]FDG PET-CT scanning.
  • METHODS: The study population consisted of 70 patients who had prior preoperative radiochemotherapy and surgical resection of the primary tumor and who underwent whole body [¹⁸F]FDG PET-CT scanning for the detection of recurrent disease.
  • The final diagnosis was based on pathological proof or clinical and/or imaging follow-up data.
  • Of these, 11 (41%) patients had a local tumor recurrence and 16 (59%) had no recurrent tumor.
  • Among the 43 patients without increased [¹⁸F]FDG uptake at the peri-anastomosis, none had local tumor recurrence.
  • However, when the time period between surgery and [¹⁸F]FDG PET-CT scanning was taken into account, overlap of SUV(max) was mainly observed within a postoperative period of ≤12 months; thereafter, a threshold SUV(max) of 3.2 discriminated between benign and malignant lesions in all but one patient.
  • CONCLUSION: In our series, visually increased [¹⁸F]FDG uptake at the peri-anastomosis was 100% sensitive but non-specific (73% specificity) for the diagnosis of local tumor recurrence.
  • On the other hand, normal [¹⁸F]FDG uptake at the peri-anastomosis precluded a local tumor recurrence (a negative predictive value of 100%).
  • [MeSH-major] Colorectal Neoplasms / radiography. Colorectal Neoplasms / radionuclide imaging
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Humans. Inflammation / radiography. Inflammation / radionuclide imaging. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20639817.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


100. Shantha Kumara HM, Grieco MJ, Yan X, Kalady MF, DiMaggio V, Kim DG, Hyman N, Feingold DL, Whelan RL: Minimally invasive colorectal resection for cancer is associated with a short-lived decrease in soluble Tie-2 receptor levels, which may transiently inhibit VEGF-mediated angiogenesis (via altered blood levels of free Ang-1 and Ang-2). Surg Endosc; 2010 Oct;24(10):2581-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive colorectal resection for cancer is associated with a short-lived decrease in soluble Tie-2 receptor levels, which may transiently inhibit VEGF-mediated angiogenesis (via altered blood levels of free Ang-1 and Ang-2).
  • After minimally invasive colorectal resection (MICR), Ang-1 levels decrease and Ang-2 levels increase, which may stimulate angiogenesis in wounds and residual tumor foci.
  • METHODS: Blood samples were taken preoperatively (PreOp) and on postoperative days (POD) 1 and 3 from 50 cancer and 53 benign disease MICR patients.
  • RESULTS: PreOp plasma sTie-2 levels were significantly higher in the benign group (27.6 ± 10.2) than in the cancer group (22.9 ± 7.9).
  • A significant drop from PreOp occurred in sTie-2 levels in the cancer group on POD1 (20.0 ± 7.4) and POD3 (21.0 ± 6.6) and in the benign group on POD1 (24.8 ± 9.1).
  • The benign group's POD3 and the cancer group's POD7-13 sTie-2 levels were statistically similar to the PreOp levels while the benign group's POD7-13 level was significantly higher.
  • The benign group's early results were similar.
  • [MeSH-major] Angiopoietin-2 / blood. Colectomy. Colorectal Neoplasms / surgery. Neovascularization, Pathologic / physiopathology. Receptor, TIE-2 / blood. Rectum / surgery. Vascular Endothelial Growth Factors / physiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 Aug;25(8):2769-70 [21487885.001]
  • [Cites] J Cell Sci. 2005 Feb 15;118(Pt 4):771-80 [15687104.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] J Am Coll Cardiol. 2004 Feb 4;43(3):423-8 [15013125.001]
  • [Cites] Br J Surg. 2001 Apr;88(4):539-44 [11298622.001]
  • [Cites] Ann Surg. 1966 Sep;164(3):491-502 [5951515.001]
  • [Cites] Eur J Surg Oncol. 2007 Dec;33(10):1169-76 [17512160.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):295-301 [18782657.001]
  • [Cites] Br J Surg. 1993 Jun;80(6):777-80 [7687189.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):973-7 [19474682.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2007 Dec;27(12 ):2619-26 [17901375.001]
  • [Cites] Surgery. 1986 Aug;100(2):273-7 [3738755.001]
  • [Cites] Surgery. 1987 Jul;102(1):71-8 [3495896.001]
  • [Cites] Br J Cancer. 1996 Jul;74(1):69-72 [8679461.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):233-5 [10064753.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2072-8 [9329972.001]
  • [Cites] Circulation. 2004 Oct 19;110(16):2355-60 [15302795.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):755-64 [16114015.001]
  • [Cites] Eur J Clin Invest. 2003 Jul;33(7):529-35 [12814387.001]
  • [Cites] Surgery. 2004 Aug;136(2):205-9 [15300181.001]
  • [Cites] Surg Endosc. 1998 Aug;12(8):1035-8 [9685537.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Surgery. 2002 Aug;132(2):186-92 [12219010.001]
  • [Cites] Eur J Clin Invest. 2006 Feb;36(2):127-32 [16436095.001]
  • [Cites] Mol Cell Biol. 2009 Apr;29(8):2011-22 [19223473.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2353-7 [15330184.001]
  • [Cites] Angiogenesis. 2001;4(2):123-31 [11806244.001]
  • [Cites] Surgery. 2003 Sep;134(3):432-6 [14555930.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):792-8 [17060773.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6571-7 [7987857.001]
  • [Cites] World J Gastroenterol. 2005 Feb 21;11(7):964-9 [15742397.001]
  • [Cites] J Intern Med. 2005 Oct;258(4):336-43 [16164572.001]
  • [Cites] Br J Surg. 1985 Oct;72(10):771-6 [2412626.001]
  • (PMID = 20354881.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiopoietin-2; 0 / Vascular Endothelial Growth Factors; EC 2.7.10.1 / Receptor, TIE-2
  •  go-up   go-down






Advertisement